<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002146" GROUP_ID="HTN" ID="546100021713415261" MERGED_FROM="" MODIFIED="2008-08-13 12:00:49 +0200" MODIFIED_BY="Ciprian Jauca" REVIEW_NO="A005" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-08-13 12:00:49 +0200" MODIFIED_BY="Ciprian Jauca">
<TITLE>Pharmacotherapy for hypertension in women of different races</TITLE>
<CONTACT MODIFIED="2008-08-13 12:00:49 +0200" MODIFIED_BY="Ciprian Jauca"><PERSON ID="14188" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anna</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Quan</LAST_NAME><POSITION>Attending physician, Assistant Professor of Medicine</POSITION><EMAIL_1>anna.quan@med.va.gov</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Internal Medicine</DEPARTMENT><ORGANISATION>San Diego VAMC, UC San Diego</ORGANISATION><ADDRESS_1>3350 La Jolla Village Drive , 111N</ADDRESS_1><CITY>San Diego</CITY><ZIP>92161</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1-858-552-8585 ext: 2811</PHONE_1><PHONE_2>+1-619-601-2547</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-13 12:00:49 +0200" MODIFIED_BY="Ciprian Jauca"><PERSON ID="14188" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anna</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Quan</LAST_NAME><POSITION>Attending physician, Assistant Professor of Medicine</POSITION><EMAIL_1>anna.quan@med.va.gov</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Internal Medicine</DEPARTMENT><ORGANISATION>San Diego VAMC, UC San Diego</ORGANISATION><ADDRESS_1>3350 La Jolla Village Drive , 111N</ADDRESS_1><CITY>San Diego</CITY><ZIP>92161</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1-858-552-8585 ext: 2811</PHONE_1><PHONE_2>+1-619-601-2547</PHONE_2></ADDRESS></PERSON><PERSON ID="14175" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Karla</FIRST_NAME><LAST_NAME>Kerlikowske</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>kerliko@itsa.ucsf.edu</EMAIL_1><EMAIL_2>karla_kerlikowske@quickmail.ucsf.edu</EMAIL_2><ADDRESS><DEPARTMENT>Medicine and Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of California, San Franciso</ORGANISATION><ADDRESS_1>4150 Clement Street</ADDRESS_1><ADDRESS_2>VAMC (111A1)</ADDRESS_2><CITY>San Franciso</CITY><ZIP>92121</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="5749" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Francois</FIRST_NAME><LAST_NAME>Gueyffier</LAST_NAME><EMAIL_1>francois.gueyffier@chu-lyon.fr</EMAIL_1><ADDRESS><DEPARTMENT>Centre d'Investigation Clinique - CIC de Lyon</DEPARTMENT><ORGANISATION>Hopital Cardio-Vasculaire et Pneumologique Louis Pradel</ORGANISATION><ADDRESS_1>28 Avenue du Doyen Lépine</ADDRESS_1><CITY>Bron</CITY><ZIP>69677</ZIP><REGION>CEDEX</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>00 33 (0)4 72 35 72 31</PHONE_1><FAX_1>00 33 (0)4 72 35 73 64</FAX_1></ADDRESS></PERSON><PERSON ID="5695" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jean-Pierre</FIRST_NAME><LAST_NAME>Boissel</LAST_NAME><EMAIL_1>jpb@upcl.univ-lyon1.fr</EMAIL_1><ADDRESS><DEPARTMENT>Centre d'Investigation Clinique - CIC de Lyon</DEPARTMENT><ORGANISATION>Hopital Cardio-Vasculaire et Pneumologique Louis Pradel</ORGANISATION><CITY>Bron</CITY><ZIP>69677</ZIP><REGION>CEDEX</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 478782834</PHONE_1><FAX_1>+33 478782838</FAX_1></ADDRESS></PERSON><PERSON ID="14171" ROLE="AUTHOR"><FIRST_NAME/><LAST_NAME>INDANA Investigators</LAST_NAME><ADDRESS><DEPARTMENT>Centre d'Investigation Clinique - CIC de Lyon</DEPARTMENT><ORGANISATION>Hopital Cardio-Vasculaire et Pneumologique Louis Pradel</ORGANISATION><CITY>Bron</CITY><ZIP>69677</ZIP><REGION>CEDEX</REGION><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-13 12:00:49 +0200" MODIFIED_BY="Ciprian Jauca">
<UP_TO_DATE>
<DATE DAY="3" MONTH="12" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="12" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="4" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2000"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-13 12:57:17 +0300" MODIFIED_BY="Ciprian D Jauca">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-13 12:57:17 +0300" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="26" MONTH="2" YEAR="2003"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Association pour la Promotion de la Recherche et de l'Evaluation en Therapeutiq</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Societe Francaise d'Hypertension Arterielle</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Fondation pour la Recherche Medicale</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Hospices Civils de Lyon</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-13 12:58:11 +0300" MODIFIED_BY="Ciprian D Jauca">
<SUMMARY MODIFIED="2008-08-13 12:58:11 +0300" MODIFIED_BY="Ciprian D Jauca">
<TITLE MODIFIED="2008-08-13 12:58:11 +0300" MODIFIED_BY="Ciprian D Jauca">Treating hypertension greatly reduces the risk of serious health problems such as heart disease or stroke in African American women and in older women</TITLE>
<SUMMARY_BODY>
<P>Hypertension (high blood pressure) is a risk factor for heart disease and stroke. Several treatments exist, including many drugs, to try to lower blood pressure and reduce the risk of serious health problems. Hypertension is a significant risk for heart disease in women, and certain groups such as African American women or older women (over 55 years) are more likely to suffer from hypertension. The review found that treating women for hypertension greatly reduced the risk of heart disease and stroke in older women and in African American women of all ages. Treating hypertension in these women is therefore important.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Although hypertension treatment in women is recommended to decrease the risk of cardiovascular disease (Wenger 1993, Kaplan 1995, Kuhn 1993, Hayes 1998, JNCVI,1997), the evidence for treatment benefit is primarily based on combined results for men and women (Collins 1990, Insua 1994, Mulrow 1994, Psaty 1997). </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess whether the relative and absolute benefit of hypertension treatment in women varies with age or race.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Literature search of studies from 1966 to 1998 using MEDLINE, reviews, and consultation with experts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Studies were eligible if they were randomized controlled trials of pharmacological treatment of primary hypertension, with cardiovascular morbidity and mortality outcomes, and with over one hundred women enrolled.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The pooled population included 23,000 women. Relative risks were combined for each endpoint to form summary risk ratios (RR) using meta-analytic techniques based on a random-effects model. Summary RR's were converted to numbers needed to treat (NNT). Data were dichotomized by age to approximate menopausal status (30 to 54 years, and 55 years and older), and by race (white and African American).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>In women ages 55 years or older (90% white), hypertension treatment results in a 38% risk reduction in fatal and nonfatal cerebrovascular events (95% confidence interval (CI) 27-47%, 5 year NNT 78), a 25% reduction in fatal and nonfatal cardiovascular events (95% CI 17-33%, 5 year NNT 58), and a 17% reduction in cardiovascular mortality (95% CI 3-29%, 5 year NNT 282). In women ages 30 to 54 years (79% white), hypertension treatment results in a 41% risk reduction in fatal and nonfatal cerebrovascular events (95% CI 8-63%, 5 year NNT 264), and a 27% risk reduction in fatal and nonfatal cardiovascular events (95% CI 4-44%, 5 year NNT 259). Hypertension treatment in African American women (mean age 52 years) reduced the risk of fatal and nonfatal cerebrovascular events by 53% (95% CI 29-69%, 5 year NNT 39), fatal and nonfatal cardiovascular events by 45% (95% CI 18-63%, 5 year NNT 21), fatal and nonfatal coronary events by 33% (95% CI 6-52%, 5 year NNT 48), and all cause mortality by 34% (95% CI 14-49%, 5 year NNT 32). Analyses in white women 30 to 54 years old did not show any statistically significant treatment benefit or harm.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Hypertension treatment lowers the relative and absolute risk of cardiovascular morbidity and mortality in women ages 55 years and older, and in African American women of all ages. A greater effort should be made to increase awareness and treatment in these groups of women. Although relative risk reductions for cerebrovascular and cardiovascular events are similar for younger and older women, the NNT of younger women is at least 4 times higher. Decisions for treatment of hypertension in younger white women should be influenced by the individual patient's absolute risk of cardiovascular disease.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Although hypertension treatment in women is recommended to decrease the risk of cardiovascular disease (<LINK REF="REF-Wenger-1993" TYPE="REFERENCE">Wenger 1993</LINK>, <LINK REF="REF-Kaplan-1995" TYPE="REFERENCE">Kaplan 1995</LINK>, <LINK REF="REF-Kuhn-1993" TYPE="REFERENCE">Kuhn 1993</LINK>, <LINK REF="REF-Hayes-1998" TYPE="REFERENCE">Hayes 1998</LINK>, JNCVI,1997). The evidence for treatment benefit is primarily based on combined results for men and women (<LINK REF="REF-Collins-1990" TYPE="REFERENCE">Collins 1990</LINK>, <LINK REF="REF-Insua-1994" TYPE="REFERENCE">Insua 1994</LINK>, <LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>, <LINK REF="REF-Psaty-1997" TYPE="REFERENCE">Psaty 1997</LINK>). Recently the INDANA group assessed the benefit of hypertension treatment in women by pooling data for women participants from seven randomized controlled trials(<LINK REF="REF-Gueyffier-1997" TYPE="REFERENCE">Gueyffier 1997</LINK>). Results showed a significant 29% risk reduction in fatal cerebrovascular events, 38% risk reduction for non-fatal and fatal cerebrovascular events, and 26% risk reduction for cardiovascular events in women the magnitude of the risk reduction was similar to that in men, although hypertension treatment in men also significantly decreased fatal and non-fatal coronary events and total mortality. </P>
<P>Although the INDANA study is the most complete quantitative review of hypertension treatment in women to date, data confirming a significant clinical benefit in younger women are lacking (<LINK REF="REF-Anastos-1991" TYPE="REFERENCE">Anastos 1991</LINK>, <LINK REF="REF-Schnall-1984" TYPE="REFERENCE">Schnall 1984</LINK>, <LINK REF="REF-Hayes-1998" TYPE="REFERENCE">Hayes 1998</LINK>). Subgroup analyses according to gender in the Medical Research Council (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK>) and Hypertension Detection and Follow-up Program (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) trials, both with a mean population age of 51 years, suggest an increase in total mortality ranging from 2.5% to 26% among women treated for hypertension. In contrast, a subgroup analysis of men in the same trials shows significant risk reduction in mortality and cerebrovascular events( <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>). Although these subgroup analyses in younger women have inadequate statistical power to allow a meaningful conclusion, the lack of a clear treatment benefit and the possibility of harm raise the question of whether treating hypertension in a low cardiovascular risk group, such as young women, is clinically beneficial.</P>
<P>Subgroup analyses of African American women from individual studies show a trend towards benefit with hypertension treatment, but the statistical significance of the analyses were not published (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>, <LINK REF="STD-Shep" TYPE="STUDY">Shep</LINK>). Data from randomized studies have not been pooled to determine a more stable risk estimate in African American women treated for hypertension. Yet, the magnitude of treatment benefit is an important clinical issue since hypertension is a major health problem in African American women. The prevalence of hypertension in African American women (23%) is nearly double that of white women (12%) (<LINK REF="REF-Burt-1995" TYPE="REFERENCE">Burt 1995</LINK>). The higher prevalence and earlier onset of hypertension in African American women contribute to a more severe course and a higher incidence of cardiovascular morbidity and mortality at younger ages, including higher rates of stroke mortality, coronary disease mortality, and end-stage renal disease, compared to non-hypertensives (<LINK REF="REF-Croog-1990" TYPE="REFERENCE">Croog 1990</LINK>, <LINK REF="REF-Saunders-1985" TYPE="REFERENCE">Saunders 1985</LINK>, <LINK REF="REF-Sixth-report-1997" TYPE="REFERENCE">Sixth report 1997</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>We used meta-analytic techniques to combine data from randomized controlled trials to determine whether the benefit of treating hypertension in women differed significantly between younger versus older women, and between white versus African American women. We also calculated the number needed to treat (NNT) according to age and race to assess the absolute clinical benefit of treating hypertension in these subgroups of women.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized controlled studies</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>The population included greater than 100 women with essential hypertension. Hypertension was defined as diastolic &gt; 89 mm Hg, systolic &gt; 139 mm Hg or isolated systolic &gt; 159 mm Hg with &lt; 90 mm Hg diastolic</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>An intervention group received treatment with either a single or multiple pharmacologic agents, and a control group received either placebo or standard of care,</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>To be included, we required individual patient endpoints to be available according to gender and/or race. Study outcomes were defined similarly to previous hypertension meta-analyses 8, 10 according to cardiovascular morbidity and mortality events: 1) fatal cerebrovascular events, 2) combined fatal and non-fatal cerebrovascular events, excluding transient ischemic attacks 3) fatal coronary events, defined as either myocardial infarction or sudden cardiac death, 4) combined fatal coronary events and non-fatal myocardial infarctions, 5) combined fatal cardiovascular events, including category one and three above and fatal pulmonary embolus and ruptured aortic aneurysm, 6) combined fatal and non-fatal cardiovascular events (non-fatal cerebrovascular accidents and non-fatal myocardial infarctions), and 7) death from any cause. A cerebrovascular event was defined as a persistent neurologic deficit lasting 24 hours or more with or without verification by radiological imaging, and myocardial infarction was defined as persistent ischemic electrocardiogram changes, or verified enzyme elevation.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We performed a literature search of studies published between 1966 and September, 1998 using the MEDLINE computer database and the following MESH terms: HYPERTENSION, WOMEN, and MORTALITY or STROKE, and RANDOMIZED CONTROLLED TRIAL and ENGLISH. Additional studies were identified from review articles and consultation with experts. In the case of multiple publications from a single study, we used the most recent publication. </P>
<P>Through our MEDLINE search, we retrieved 270 articles. Seven more articles (<LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>, <LINK REF="REF-Helgeland-1980" TYPE="REFERENCE">Helgeland 1980</LINK>, <LINK REF="REF-Kuramoto-1981" TYPE="REFERENCE">Kuramoto 1981</LINK>, <LINK REF="REF-Wolff-1966" TYPE="REFERENCE">Wolff 1966</LINK>, <LINK REF="STD-VA115_x002d_129" TYPE="STUDY">VA115-129</LINK>, <LINK REF="STD-VA90_x002d_114" TYPE="STUDY">VA90-114</LINK>, <LINK REF="STD-VAfeasibility" TYPE="STUDY">VAfeasibility</LINK>) were found from references in review articles. Of the 277 eligible articles, forty-four articles were multiple publications from the same studies. The other major reasons for study exclusion are shown in Table 1. Thirty-four randomized controlled studies of treatment for essential hypertension were identified. After applying inclusion criteria, only eleven studies remained eligible (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>, <LINK REF="STD-Shep" TYPE="STUDY">Shep</LINK>, <LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, older 1992, <LINK REF="REF-Perry-1989" TYPE="REFERENCE">Perry 1989</LINK>, <LINK REF="REF-Casiglia-1994" TYPE="REFERENCE">Casiglia 1994</LINK>, <LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>, <LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>, <LINK REF="REF-Amery-1985" TYPE="REFERENCE">Amery 1985</LINK>, <LINK REF="REF-Coope-1986" TYPE="REFERENCE">Coope 1986</LINK>, <LINK REF="REF-Dahlof-1991" TYPE="REFERENCE">Dahlof 1991</LINK>). Of the twenty-three other studies, seven studies included no women, (<LINK REF="REF-Helgeland-1980" TYPE="REFERENCE">Helgeland 1980</LINK>, <LINK REF="REF-Veterans-1967" TYPE="REFERENCE">Veterans 1967</LINK>, <LINK REF="REF-Veterans-1970" TYPE="REFERENCE">Veterans 1970</LINK>, <LINK REF="REF-VA_x002d_NHLBI-1978" TYPE="REFERENCE">VA-NHLBI 1978</LINK>, <LINK REF="REF-Wikstrand-1998" TYPE="REFERENCE">Wikstrand 1998</LINK>, <LINK REF="REF-Wilhelmsen-1987" TYPE="REFERENCE">Wilhelmsen 1987</LINK>, <LINK REF="STD-MRFIT" TYPE="STUDY">MRFIT</LINK>) and five studies included fewer than 100 women (<LINK REF="REF-Kuramoto-1981" TYPE="REFERENCE">Kuramoto 1981</LINK>, <LINK REF="REF-Wolff-1966" TYPE="REFERENCE">Wolff 1966</LINK>, <LINK REF="REF-Smith-1977" TYPE="REFERENCE">Smith 1977</LINK>, <LINK REF="STD-Barraclough" TYPE="STUDY">Barraclough</LINK>, <LINK REF="REF-Sprackling-1981" TYPE="REFERENCE">Sprackling 1981</LINK> ) The other eleven randomized controlled trials with cardiovascular outcomes were not included because studies are currently ongoing, (<LINK REF="REF-Davis-1996" TYPE="REFERENCE">Davis 1996</LINK>, <LINK REF="REF-Malacco-1994" TYPE="REFERENCE">Malacco 1994</LINK>, <LINK REF="REF-Dahlof-1991" TYPE="REFERENCE">Dahlof 1991</LINK>, <LINK REF="REF-Wing-1997" TYPE="REFERENCE">Wing 1997</LINK>, <LINK REF="REF-Lindholm-1996" TYPE="REFERENCE">Lindholm 1996</LINK>) data were unattainable from primary authors, (<LINK REF="REF-Neaton-1993" TYPE="REFERENCE">Neaton 1993</LINK>) or two treatment groups were compared, rather than comparing a treatment group to placebo or usual care (<LINK REF="REF-Hannson-1994" TYPE="REFERENCE">Hannson 1994</LINK>, <LINK REF="STD-BBB" TYPE="STUDY">BBB</LINK>, <LINK REF="STD-IPPPSH" TYPE="STUDY">IPPPSH</LINK>, <LINK REF="REF-Hansson-1998" TYPE="REFERENCE">Hansson 1998</LINK>, <LINK REF="STD-HOT" TYPE="STUDY">HOT</LINK>, <LINK REF="REF-Estacio-1998" TYPE="REFERENCE">Estacio 1998</LINK>, <LINK REF="REF-Tatti-1998" TYPE="REFERENCE">Tatti 1998</LINK>).<BR/>Table 1: Reasons for Exclusion of Studies</P>
<P>Primary Reason for Exclusion Number of Reports<BR/>Not a randomized controlled trial 18<BR/>No women included 7<BR/>Fewer than 100 women in study 5<BR/>Not essential hypertension 91<BR/>No pharmacological intervention/no control 29<BR/>No cardiovascular morbidity or mortality outcomes 66<BR/>Data still in collection phase 5<BR/>No data available by gender and age 1<BR/>(Multiple 1982) publications 44 <BR/>Total 266</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>We performed a literature search of studies published between 1966 and September, 1998 using the MEDLINE computer database and the following MESH terms: HYPERTENSION, WOMEN, and MORTALITY or STROKE, and RANDOMIZED CONTROLLED TRIAL and ENGLISH. Additional studies were identified from review articles and consultation with experts. In the case of multiple publications from a single study, we used the most recent publication. <BR/> Retrieved articles were selected if they met all of the following criteria: 1) the study was a randomized controlled trial, 2) the population included greater than 100 women with essential hypertension, 3) hypertension was defined as diastolic &gt; 89 mm Hg, systolic &gt; 139 mm Hg or isolated systolic &gt; 159 mm Hg with &lt; 90 mm Hg diastolic, 4) an intervention group received treatment with either a single or multiple pharmacologic agents, 5) a control group received either placebo or standard of care, 6) individual patient endpoints were available according to gender and/or race, and 7) study outcomes included cardiovascular morbidity and mortality outcomes.<BR/> Study outcomes were defined similarly to previous hypertension meta-analyses 8, 10 according to cardiovascular morbidity and mortality events: 1) fatal cerebrovascular events, 2) combined fatal and non-fatal cerebrovascular events, excluding transient ischemic attacks 3) fatal coronary events, defined as either myocardial infarction or sudden cardiac death, 4) combined fatal coronary events and non-fatal myocardial infarctions, 5) combined fatal cardiovascular events, including category one and three above and fatal pulmonary embolus and ruptured aortic aneurysm, 6) combined fatal and non-fatal cardiovascular events (non-fatal cerebrovascular accidents and non-fatal myocardial infarctions), and 7) death from any cause. A cerebrovascular event was defined as a persistent neurologic deficit lasting 24 hours or more with or without verification by radiological imaging, and myocardial infarction was defined as persistent ischemic electrocardiogram changes, or verified enzyme elevation. The definition of major outcomes of cardiovascular morbidity and mortality were similar for each study, except for the Australian Study (<LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>), 21 which reported three non-fatal outcomes that differed from the other trials (transient ischemic attacks, congestive heart failure, and evidence of hypertensive end-organ damage) and the HDPF 14 (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) which measured all cause mortality as a primary outcome, and assessed cause-specific outcomes according to coding on death certificates and retrospective patient interviews. Only fatal endpoints from the Australian Study (<LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>) (cerebrovascular events, coronary events, and cardiovascular mortality) were incorporated into the meta-analysis. For HDPF (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>), all results were incorporated into the meta-analysis.</P>
<P> Study eligibility was assessed by two reviewers according to an abstraction form designed prior to the literature search. Results for women participants in studies were available from publications, (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, older, 1992) primary authors, (<LINK REF="REF-Perry-1989" TYPE="REFERENCE">Perry 1989</LINK>, <LINK REF="REF-Casiglia-1994" TYPE="REFERENCE">Casiglia 1994</LINK>, <LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>) and from the INDANA hypertension database, (<LINK REF="REF-Gueyffier-1997" TYPE="REFERENCE">Gueyffier 1997</LINK>) which had independently collected individual patient outcome data from two of the published studies, (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, older 1992) as well as six other eligible studies. (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>,<LINK REF="STD-Shep" TYPE="STUDY">Shep</LINK>, <LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>, <LINK REF="REF-Amery-1985" TYPE="REFERENCE">Amery 1985</LINK>, <LINK REF="REF-Coope-1986" TYPE="REFERENCE">Coope 1986</LINK>, <LINK REF="REF-Dahlof-1991" TYPE="REFERENCE">Dahlof 1991</LINK>) Only five studies clearly specified the race of individual patients (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>, <LINK REF="REF-Perry-1989" TYPE="REFERENCE">Perry 1989</LINK>, <LINK REF="REF-Casiglia-1994" TYPE="REFERENCE">Casiglia 1994</LINK>, <LINK REF="STD-Shep" TYPE="STUDY">Shep</LINK>, <LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>). All women in the Castel and Syst-Eur studies (<LINK REF="STD-CASTEL" TYPE="STUDY">CASTEL</LINK>, <LINK REF="STD-Syst_x002d_eur" TYPE="STUDY">Syst-eur</LINK>) were white (personal communication). (<LINK REF="REF-Casiglia-1994" TYPE="REFERENCE">Casiglia 1994</LINK>, <LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>, <LINK REF="REF-Sixth-report-1997" TYPE="REFERENCE">Sixth report 1997</LINK>) other three studies are from the United States, and have only two race categories, "white" and "black". The other six studies did not designate race, but were conducted in geographic areas of Caucasian predominance. Thus, the race subgroups in our review will be designated as African American and "white," the latter of which encompasses patients of any other unspecified race included in the studies.</P>
<P>Data Synthesis<BR/>Analysis of baseline characteristics and multivariate logistic regressions were conducted in collaboration with INDANA. Percentages and means for baseline characteristics were calculated by combining individual patient data from all studies that met inclusion criteria except for SHEP pilot, CASTEL, and Syst-Eur (<LINK REF="STD-CASTEL" TYPE="STUDY">CASTEL</LINK>,<LINK REF="STD-Syst_x002d_eur" TYPE="STUDY">Syst-eur</LINK>, <LINK REF="STD-Shep-Pilot" TYPE="STUDY">Shep Pilot</LINK>) from which baseline data were not available.<BR/> To estimate the benefit of treating hypertension in women, we performed a meta-analysis using a DerSimion Laird (DL) random-effects model. Relative risks were calculated for each study and then combined to calculate summary risk ratios (RR) and 95% confidence intervals (CI) for each cardiovascular outcome. Summary estimates were calculated based on age (30 to 54 years versus 55 years and older) and race (white versus African American) in the same pooled population of women. We dichotomized the data at age 55 because by this age, 90% of women are menopausal, (<LINK REF="REF-Stanford-1987" TYPE="REFERENCE">Stanford 1987</LINK>, <LINK REF="REF-Whelan-1990" TYPE="REFERENCE">Whelan 1990</LINK>) after which cardiovascular risk begins to rise (<LINK REF="REF-US-Dept-1991" TYPE="REFERENCE">US Dept 1991</LINK>). A Chi-squared test for homogeneity was performed for all summary estimates. P values less than or equal to 0.1 were considered statistically significant. <BR/>Summary risk ratios (RRDL) were converted to numbers needed to treat (NNT) estimates, which is the number of patients who must be treated to prevent one adverse outcome <LINK REF="REF-Rajkumar-1996" TYPE="REFERENCE">Rajkumar 1996</LINK>, <LINK REF="REF-Sinclair-1994" TYPE="REFERENCE">Sinclair 1994</LINK>, <LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>, <LINK REF="REF-McQuay-1997" TYPE="REFERENCE">McQuay 1997</LINK>). The NNT was determined by calculating the absolute risk and then calculating the NNT using the following formulas where p'(C) is a pooled estimate for the proportion of events in the control group, and is calculated using the proportion of events in the control group p(C), variance (p(C)), total number of control patients n(C), and weight from individual studies.</P>
<P>Variance(p(C)) =( p(C)*(1- p(C)))/n(C)</P>
<P>Weight = 1/var (p(C))</P>
<P>p'(C) = sum (w* p(C))/sum(w)</P>
<P>The risk difference, or absolute risk for the pooled estimate is obtained using:<BR/>Absolute Risk = p'(C)* (RRDL) - p'(C)</P>
<P>NNT = 1/(Absolute Risk)</P>
<P>We standardized the NNT to 5 years, as most studies had a 5 year follow-up.</P>
<P>Standard NNT = NNT (length of follow-up/standard years) </P>
<P>The pooled length of follow-up was weighted by dividing the sum of patient years from each study by the total number of women in each subgroup. Thus, to standardize to a 5 year NNT, if the pooled length of follow-up was 4.3 years, we multiplied the calculated NNT by (4.3/5).<BR/>To test the robustness of our results for younger and older women, we conducted a multivariate analysis using a logistic regression model using pooled data with adjustment for differences in the following baseline characteristics: age, systolic and diastolic hypertension levels, cholesterol level, smoking status, diabetes mellitus, and history of prior myocardial infarction or cerebrovascular accident. A multivariate analysis was also performed to test the robustness of our results according to race adjusting for the above characteristics. P levels were calculated for interactions between age group and treatment in the age analysis and between race and treatment in the race analysis.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Eligible studies are summarized in the section of Included Studies. Studies recruited women from 30 to 98 years old, with the mean age of women across trials ranging from 50.4 to 75 years. Mean follow-up of studies ranged from 2 to 12 years. Each study used a diuretic or beta-blocker as first line therapy, except for the CASTEL study (<LINK REF="REF-Casiglia-1994" TYPE="REFERENCE">Casiglia 1994</LINK>), which allowed clonidine or nifedipine, and the Syst-Eur study (<LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>) which used nitrendipine. Table 3 shows the number of women from each study dichotomized by age and race. There were approximately 8,500 women aged 30 to 54 years, and 17,600 women 55 years and older. When the same pooled group of women are dichotomized by race, there were 23,000 white women, compared to 3,200 African American women.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>See above under the Methods of the Review section.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Table 4 summarizes pooled baseline characteristics of control and treated groups by age and race. Data on baseline characteristics were not available from CASTEL, Syst-eur and SHEP Pilot (<LINK REF="STD-CASTEL" TYPE="STUDY">CASTEL</LINK>, <LINK REF="STD-Syst_x002d_eur" TYPE="STUDY">Syst-eur</LINK>, <LINK REF="STD-Shep-Pilot" TYPE="STUDY">Shep Pilot</LINK>) studies and information on other cardiovascular risk factors, such as left ventricular hypertrophy or obesity were not collected for all of the studies. Among women 30 to 54 years (79% white) the control group had a slightly higher percentage of smokers than the treated group (33% versus 31%, P = 0.025). Among women 55 years and older (90% white) there were no significant differences in mean age, systolic and diastolic blood pressure, total cholesterol, or prevalence of smoking, diabetes, and history of cerebrovascular accidents or coronary events. When baseline characteristics of the women were examined according to race, white women treated for hypertension had a slightly higher percentage of prior myocardial infarction than the control group (1.7% versus 1.3%, P = 0.02). In comparison to white women, African American women were younger (mean age 52 years), with a higher percentage of smokers, diabetics, and history of prior myocardial infarction or cerebrovascular accident. There were no significant differences in baseline characteristics between the treated and control groups of African American women.<BR/>The summary relative risk estimates according to major cardiovascular events are shown according to age in Figures 1 and 2, and according to race in Figures 3 and 4, with vertical lines delineating the 95% CI. All combined results were found to be homogeneous (P value &gt; 0.1). In women aged 30 to 54 years treated for hypertension (N= 8,565), there was a statistically significant reduction in fatal and non-fatal cerebrovascular events (RR 0.59, 95% CI 0.37 to 0.92), and fatal and non-fatal cardiovascular events (RR 0.73, 95% CI 0.56 to 0.96). (Figure 1) There was no significant reduction or increase in coronary morbidity or mortality, cardiovascular mortality, or all cause mortality outcomes with hypertension treatment. <BR/> Figure 2 shows the summary estimates for cardiovascular outcomes in women aged 55 years and older (N= 17,604). Hypertension treatment resulted in a significant risk reduction in fatal and non-fatal cerebrovascular accidents (RR 0.62, 95% CI 0.53 to 0.73), and fatal and non-fatal cardiovascular events (RR 0.75, 95% CI 0.67 to 0.83). In addition, women aged 55 years and older treated for hypertension had a risk reduction in fatal cardiovascular events (RR 0.83, 95% CI 0.71 to 0.97) and bordered on significance for all cause mortality (RR 0.89, 95% CI 0.80-1.0). The summary estimates for coronary events were not statistically significant. <BR/> Figures 3 and 4 show the summary estimates for cardiovascular outcomes according to race. Summary estimates in white women (N= 22,963) were significant for fatal and non-fatal cerebrovascular events (RR 0.65, 95% CI 0.55-0.77), and fatal and non-fatal cardiovascular events (RR 0.78, 95% CI 0.7-0.86). However, hypertension treatment in white women of all ages did not demonstrate a reduction in coronary morbidity or mortality, cardiovascular mortality, or all cause mortality. In comparison, hypertension treatment in African American women (N= 3,206) resulted in substantial risk reduction in fatal and non-fatal cerebrovascular outcomes (RR 0.47, 95% CI 0.31-0.71), fatal and non-fatal coronary events (RR 0.67, 95% CI 0.48-0.94), fatal cardiovascular events (RR 0.65, 95% CI 0.45-0.95), fatal and non-fatal cardiovascular events (RR 0.55, 95% CI 0.37-0.82), and all cause mortality (RR 0.66, 95% CI 0.51-0.86). <BR/>When data were analysed for white women aged 30 to 54 years (N= 6,731), there were no statistically significant reductions in cardiovascular morbidity or mortality, although the trends are similar to the results in all women aged 30 to 54 years. For fatal and non-fatal cerebrovascular events, the RR was 0.62 (95%CI 0.24-1.59); for combined fatal and nonfatal coronary events, the RR was 1.4 (95% CI 0.62 -3.16); for combined fatal and non-fatal cardiovascular events, the RR was 0.74 (95% CI 0.51-1.08), and for all cause mortality, the RR was 1.08 (95% CI 0.73-1.58). <BR/>The 5 year NNT by age and race are shown in Table 5. In women aged 55 years and older, the 5 year NNT is 78 to prevent a fatal or non-fatal cerebrovascular event compared to 264 women aged 30 to 54 years. For combined fatal and non-fatal cardiovascular events, older women have a 5 year NNT of 58 versus a 259 in women aged 30 to 54 years. In the race analysis, 39 African American women need to be treated to prevent a fatal or non-fatal cerebrovascular events, 48 women for fatal and non-fatal coronary events, 98 women for fatal cardiovascular events, 21 women for fatal and non-fatal cardiovascular events, and 32 women for all cause mortality. For white women, the 5 year NNT for fatal and non-fatal cerebrovascular events is 178 women, and for fatal and non-fatal cardiovascular events, 158 women. NNT's for white women 30 to 54 years old could not be calculated since summary estimates were not statistically significant.<BR/> A multivariate pooled analysis adjusting for baseline age, systolic and diastolic blood pressure, cholesterol levels, smoking status, diabetes mellitus, and history of myocardial infarction or cerebrovascular accident yielded odds ratios (Table 6) similar to the summary relative risk estimates shown in Figures 1 to 4. After adjusting for baseline characteristics, there were no significant interactions in the treatment effect between age groups (30 to 54 years versus 55 years and older) for any cardiovascular outcome. In contrast, in the race analysis, after adjustment for baseline characteristics, there was a significant difference between groups. Compared to white women, African American women treated for hypertension had a greater risk reduction in fatal cardiovascular events (p = 0.05), fatal and nonfatal cardiovascular events (P = 0.04), and all cause mortality (p = 0.003).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Case-control and cohort studies consistently show that diastolic and isolated systolic hypertension are risk factors for cardiovascular disease in women (<LINK REF="REF-Fiebach-1989" TYPE="REFERENCE">Fiebach 1989</LINK>, <LINK REF="REF-Nielsen-1995" TYPE="REFERENCE">Nielsen 1995</LINK>, <LINK REF="REF-Sigurdsson-1984" TYPE="REFERENCE">Sigurdsson 1984</LINK>, <LINK REF="REF-Perlman-1988" TYPE="REFERENCE">Perlman 1988</LINK>). Furthermore, combined data from women in randomized controlled trials show that treating hypertension in women reduces the risk of fatal and non-fatal cerebrovascular and cardiovascular events. (<LINK REF="REF-Gueyffier-1997" TYPE="REFERENCE">Gueyffier 1997</LINK>) Our study adds to this body of knowledge by quantitating the treatment benefit in women according to age and race. Our results demonstrate a significant relative risk reduction in cardiovascular outcomes in both younger and older women, and both white and African American women. African American women had the greatest magnitude of relative risk reduction in cardiovascular outcomes. We also found that the greatest absolute benefit occurs in African American women and women 55 years and older. In comparison, younger white women, who have a lower prevalence of cardiovascular disease, have 5 year NNT's 3 to 4 times higher than older women.<BR/>Our results affirm that hypertension treatment markedly decreases the risk of cerebrovascular and cardiovascular morbidity and mortality in women 55 years and older. By this age, 90% of women are likely post-menopausal with cardiovascular risk approaching the level of age-matched men ([<LINK REF="REF-Stanford-1987" TYPE="REFERENCE">Stanford 1987</LINK>, <LINK REF="REF-Whelan-1990" TYPE="REFERENCE">Whelan 1990</LINK>). Although results combined for both men and women demonstrated a reduction in coronary events, (<LINK REF="REF-Insua-1994" TYPE="REFERENCE">Insua 1994</LINK>, <LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>, Lever 1995, <LINK REF="REF-MacMahon-1993" TYPE="REFERENCE">MacMahon 1993</LINK>), we did not observe a significant coronary risk reduction in older women. Since the confidence intervals for the summary estimate for coronary events are wide, we may have inadequate numbers to provide statistical power to demonstrate a significant reduction in coronary death. <BR/>For cerebrovascular and cardiovascular outcomes, our group of older women had similar relative risk reductions but slightly higher 5 year NNT's, compared to other studies in elderly hypertensive men and women. (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>, Lever 1995, <LINK REF="REF-MacMahon-1993" TYPE="REFERENCE">MacMahon 1993</LINK>, <LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>) For instance, in all cardiovascular events, the 5 year NNT was 18 in a meta-analysis of elderly hypertensive men and women (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>) and was 18.5 in the Syst-Eur randomized trial of elderly hypertensives, (<LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>) compared to 58 in our older women. Likewise, for all cerebrovascular events, the 5 year NNT was 43 for elderly men and women (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>) and 34.5 in Syst-Eur, (<LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>) compared to 78 in our older women. The difference in magnitude of benefit may, in part, be due to a lower mean age in our pooled older women (mean age 66 years), (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>) compared to the elderly population in the meta-analysis (mean age 72 years) and in (<LINK REF="STD-Syst_x002d_eur" TYPE="STUDY">Syst-eur</LINK>) (mean age 70.2 years) (<LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>). Besides a lower mean age, our pooled population of older women also had lower rates of comorbidities, such as prior myocardial infarction, cerebrovascular accidents, or diabetes. Comparatively, in the Syst-eur Study (<LINK REF="STD-Syst_x002d_eur" TYPE="STUDY">Syst-eur</LINK>) alone, 30% of the enrolled population had a history of cardiovascular complications, and thus higher baseline risk for a repeat cardiovascular event. Thus, our 5 year NNT numbers are best applied to women in the community with mild hypertension.<BR/> Age subgroup analyses from INDANA and (<LINK REF="STD-Syst_x002d_eur" TYPE="STUDY">Syst-eur</LINK>) suggest an upper limit to the mortality treatment benefit for hypertension (<LINK REF="REF-Gueyffier-1997" TYPE="REFERENCE">Gueyffier 1997</LINK>, <LINK REF="REF-Staessen-1997" TYPE="REFERENCE">Staessen 1997</LINK>). Both studies did not find a mortality benefit with hypertension treatment in men and women beyond the age of 80. There was, however, significant risk reduction in cardiovascular and cerebrovascular morbidity in both studies. In our group of older women (mean age 66), the relative risk reduction in cardiovascular mortality was statistically significant, and the risk reduction of all cause mortality bordered on statistical significance. Unfortunately, we lacked the power to analyzer results by decade of age to determine a specific age threshold above which hypertension treatment no longer affects mortality. <BR/>Our study is the first to combine data from randomized controlled trials to quantitate the benefit of treating hypertension in African American women. Our results show a substantial benefit in African American women treated for hypertension in the outcomes of cerebrovascular events, coronary events, cardiovascular mortality, and all-cause mortality. Despite a mean age of 52 years, African American women in our study have an absolute benefit comparable to elderly men and women with a mean age of 72 years treated for hypertension (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>). Since the treatment benefit appears to extend to both younger and older African American women, we recommend that African American women with hypertension be <BR/>treated irrespective of their age. <BR/>The treatment benefit stems, in part, from the higher absolute risk for cardiovascular disease in the pooled African American women compared to white women (Table 4). However, even after adjusting for differences in baseline characteristics, African American women treated for hypertension have a statistically significant greater relative risk reduction than white women in cardiovascular and mortality outcomes (Table 6). The reasons for a larger hypertension treatment benefit among African American women are unclear, but may be related to a higher inherent cardiovascular risk even after adjustment for baseline characteristics, a better response to treatment, or both. <BR/>Since 85% of the African American women were from the HDFP study (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) alone, the greater treatment benefit may also stem from non-drug interventions afforded to the treatment arm of the HDFP study, such as greater access of care. A unique aspect of the HDFP design was that patients were not randomized to simple treatment and placebo groups, but to "stepped care" (SC) and "referred care" (RC) groups. The SC patients were treated according to a formal plan of "steps" which added medications as necessary to maintain blood pressure control, while the RC group was released to the care of their individual doctors for "usual care" of hypertension treatment. The SC medication plan achieved higher rates of blood pressure control compared to the RC group (68% vs. 44%), possibly due to additional benefits given to the SC group including measures to improve compliance, such as pill counts, shorter appointment waiting times, formal counseling on other cardiovascular risk factors, and subsidized medications, laboratory tests, and transportation. The greater access to care for SC patients also may have improved overall health status and contributed to improved cardiovascular outcomes. On the other hand, since the (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) study had no true placebo group, the true size of the hypertension treatment effect was blunted by the large numbers of RC patients on medication (60% of RC African American women on medication by year 5, with 44% at goal blood pressure) (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>). Thus, the treatment benefit with hypertension treatment may even be greater than reported in our study.<BR/>Despite similar relative risk reductions in cardiovascular and cerebrovascular outcomes in women 30 to 54 compared to women over 55 years, the 5 year NNT's are 3-4 times higher in the younger women, reflecting their lower cardiovascular risk (<LINK REF="REF-Jackson-1993" TYPE="REFERENCE">Jackson 1993</LINK>, <LINK REF="REF-Alderman-1993" TYPE="REFERENCE">Alderman 1993</LINK>, <LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>). Undoubtedly, the significant relative risk reductions seen in cerebrovascular and cardiovascular outcomes in women 30 to 54 years are partially driven by the African American women, who comprised 21% of the younger subgroup of women. Unfortunately, there were not enough events in white women aged 30 to 54 years to obtain a stable summary risk estimate. Thus, in treatment of hypertension in younger white women, our results support neither benefit nor harm, as suggested by subgroup analysis of white women in MRC and HDFP (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) studies. However, a true treatment benefit may have been blunted in younger white women by two factors: the partial treatment of control groups and the low cardiovascular risk status of young women enrolled in the studies. In the MRC (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>) and Australian Studies (<LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>), 10-12% of control patients received medication, and in the HDFP study (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>), 64% of RC patients received medication. However, a large absolute benefit from hypertension treatment was observed among older women and African American women, who had similar rates of hypertension treatment in control groups. Thus, the higher NNT's in younger women in our results probably reflect a lower prevalence of cardiovascular disease, not an underestimation of treatment effect from contamination of the control group. Also, the three studies with women under 55 years (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>, <LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>) recruited people through community screening and excluded many with significant systemic disease, so the NNT calculated for women aged 30 to 54 years in our study pertains to a relatively healthy population of younger women. <BR/>The higher NNT to prevent a cardiovascular event in younger white women results in higher costs per event prevented than treating older women or African American women. In general, $50,000 per year of life gained is considered an accepted cost for a medical intervention. One cost analysis of hypertension treatment based on a meta-analysis of hypertension trials estimates a cost of $229,000 per life-year gained for treating a 40 year old hypertensive woman, compared with a savings of $161,000 to treat a 70 year old woman with hypertension (<LINK REF="REF-Johannesson-1993" TYPE="REFERENCE">Johannesson 1993</LINK>, <LINK REF="REF-Johannesson-1993" TYPE="REFERENCE">Johannesson 1993</LINK>). These cost analyses did not consider race. <BR/>Since the data for white women aged 30 to 54 years is not as convincing as for older women or African American women, risk stratification of younger white women with hypertension would help to identify the younger women who may benefit most from treatment (<LINK REF="REF-Jackson-1993" TYPE="REFERENCE">Jackson 1993</LINK>, <LINK REF="REF-Kannel-1992" TYPE="REFERENCE">Kannel 1992</LINK>, <LINK REF="REF-Anderson-1991" TYPE="REFERENCE">Anderson 1991</LINK>, <LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>). For example, a 40 year old woman with a blood pressure of 160/95 but no other cardiovascular risk factors has less than a 5% chance of a cardiovascular event within 10 years; if she is diabetic with evidence of LVH, her chance increases to 33%. In comparison, a 60 year old woman with a blood pressure of 160/90 has a baseline 20% risk of a cardiovascular event within 10 years; with diabetes, her risk approaches 40% (<LINK REF="REF-Anderson-1991" TYPE="REFERENCE">Anderson 1991</LINK>). The new Joint National Committee (JNC) VI hypertension guidelines advocate a risk stratification with lifestyle modification for up to a year in those with mild hypertension (&lt;160/&lt;100) and no risk factors or end organ disease.[JNC VI, 1997]<BR/> Our study has several limitations. First there were too few events in women for several outcomes, limiting our ability to detect a significant effect. This was most problematic in coronary outcomes and all outcomes in younger white women. Also, evidence of end organ damage, such as LVH, was not included as a study outcome. These subclinical events may be more likely in younger hypertensive women than severe cardiovascular events in the first five years of treatment. Thus, a greater treatment benefit may have been noted in younger women if subclinical events were included as outcomes. We were not able to evaluate the long-term benefit or harm of treating younger women since the follow-up period for most studies ranged from 2.2 to 5 years. The only study with a 12 year follow-up period was in an elderly population. (<LINK REF="REF-Casiglia-1994" TYPE="REFERENCE">Casiglia 1994</LINK>) It is possible that treatment of hypertension in young women would result in decreased risk of cardiovascular events over a longer period of time. Of note, however, hypertension trials in the elderly clearly demonstrate that a significant risk reduction is attainable within a few years with initiation of treatment at older ages. (<LINK REF="REF-Sixth-report-1997" TYPE="REFERENCE">Sixth report 1997</LINK>, <LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>) and European Working Party Hypertension trial in the Elderly (<LINK REF="REF-Amery-1985" TYPE="REFERENCE">Amery 1985</LINK>) both stopped following patients after a nonfatal event, which may result in an underestimation for mortality outcomes. However, the underestimation should equally affect both control and treated populations and consequently should influence only the confidence intervals surrounding the summary estimates, not the summary estimates themselves. We were not able to obtain results according to gender from one eligible study, the Treatment of Mild Hypertension Study (Tomhs) (<LINK REF="REF-Neaton-1993" TYPE="REFERENCE">Neaton 1993</LINK>). However, the Tomhs trial included only 345 women, who had low event rates and would not likely influence our results. As mentioned, our pooled data for African American women came only from three studies, (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>,<LINK REF="STD-Shep" TYPE="STUDY">Shep</LINK>, <LINK REF="REF-Perry-1989" TYPE="REFERENCE">Perry 1989</LINK>) as did the data for women 30 to 54 years old, (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>, <LINK REF="STD-Australian" TYPE="STUDY">Australian</LINK>) with the majority of data for African American women from HDFP (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) (85%), and the majority of data for younger women from (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>) (75%). Therefore, our results for African American and younger women are most generalizable to hypertensive women who are similar to the study populations enrolled in (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>) and (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>), respectively.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>In conclusion, hypertension treatment greatly decreases the relative and absolute risk of cerebrovascular and cardiovascular outcomes in women 55 years and older and in both younger and older African American women. African American women treated for hypertension also have significant risk reduction in coronary and all cause mortality outcomes. A greater effort should be made to treat hypertension in these groups of women. In contrast, treatment of hypertension in white women aged 30 to 54 years old did not show statistically significant benefit or harm. Decisions for treatment of hypertension in younger white women should be influenced by the individual patient's absolute risk of cardiovascular disease.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Clearly, many other questions remain outside the scope of the present data on women and hypertension. Hopefully future studies will enrol greater numbers of younger and non-white patients in order to further clarify not only the effect of hypertension treatment, but the most effective medication choices for different subgroups, the optimal age to start or stop treatment, treatment effects in patients with specific comorbidities, and patient utility and compliance with treatment options.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful for the cooperation received from Dr. Steve Hulley, Dr. Jan Staessen, and Dr. Edoardo Casilglia in obtaining gender specific data from the Shep pilot (<LINK REF="STD-Shep-Pilot" TYPE="STUDY">Shep Pilot</LINK>), Syst-eur, and Castel studies, respectively. We appreciate the comments and advice received on the manuscript from Jeffrey Cutler, MD, Tord Ekbom, MD, Lawrence Friedman, MD, Eleanor Schron, MS, RN, and Terrie Mendelson, MD.</P>
<P>The INDANA Steering Committee includes the following members: JP Boissel, F Boutitie, F Gueyffier (Clinical Pharmacology Department, Claude Bernard University (EA 643), Lyon Hospitals, France), J Cutler, L Friedman, E Schron (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA), S Pocock (London School of Hygiene and Tropical Medicine, London, UK), J Coope (General Practice, Bollington, UK), T Ekbom (Department of Community Health Sciences, Lund University, Sweden), R Fagard (Hypertension and Cardiovascular Rehabilitation Unit, Leuven, Belgium), Karla Kerlikowske (Veterans Administration Medical Center, San Francisco, CA, USA), M Perry (Washington University School of Medicine, St. Louis, MO, USA), R Prineas (Department of Epidemiology and Public Health, Miami, FL, US</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The INDANA data base was supported by grants from the Association pour la Promotion de la Recherche et de l'Evaluation en Therapeutique, the Societe Francaise d'Hypertension Arterielle, the Fondation pour la Recherche Medicale, and the Hospices Civils de Lyon. However, we do not see any potential conflict of interest through the INDANA grants, or from the conclusions made in our study.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>A Quan - Formulated the study question, did the literature search, gathered data from multuiple sources, entered and analyzed the data for the meta -analysis models, and wrote the manuscript</P>
<P>K Kerlikowske - Formulated the study question and inclusion/exclusion criteria, evaluation of studies for inclusion, review of data analyses, and review of the manuscript</P>
<P>F Gueyffier - Coordination of the INDANA Steering Committee/ Management of the INDANA data base, Extraction of the INDANA data used in the review/ Analysis of the interactions on indivual patient data, Review of the manuscript</P>
<P>J P Boissel - Research director for INDANA project, Review of th e manuscript<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Australian" NAME="Australian" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet 1980; 1:1261-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Australian therapeutic trial in mild hypertension</AU>
<TI>Report by the Management Committee</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>1261-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-CASTEL" NAME="CASTEL" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Casiglia E, Spolaore P, Mazza A, et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly. Jpn Heart J 1994; 35:589-600.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casiglia E, Spolaore P, Mazza A, et al</AU>
<TI>Effect of two different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly</TI>
<SO>Jpn Heart J</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>589-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Coope" NAME="Coope" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986; 293:1145-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coope J, Warrender TS</AU>
<TI>Randomised trial of treatment of hypertension in elderly patients in primary care</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1986</YR>
<VL>293</VL>
<PG>1145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-EWPHE" NAME="EWPHE" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349-54.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amery A, Birkenhager W, Brixko P, et al</AU>
<TI>Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>1349-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-HDFP" NAME="HDFP" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. Jama 1979; 242:2562-71.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Five-year findings of the hypertension detection and follow-up program</AU>
<TI>I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group</TI>
<SO>Jama</SO>
<YR>1979</YR>
<VL>242</VL>
<PG>2562-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MRC" NAME="MRC" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291:97-104.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC trial of treatment of mild hypertension: principal results</AU>
<TI>Medical Research Council Working Party</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1985</YR>
<VL>291</VL>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MRC-elderly" NAME="MRC elderly" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Medical Research Council trial of treatment of hypertension in older adults: principal results. Bmj 1992; 304:405-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council</AU>
<TI>Medical Research Council trial of treatment of hypertension in older adults: principal results</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<PG>405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Shep" NAME="Shep" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [see comments]. Jama 1991; 265:3255-64.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension</AU>
<TI>Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [see comments]</TI>
<SO>Jama</SO>
<YR>1991</YR>
<VL>265</VL>
<PG>3255-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Shep-Pilot" NAME="Shep Pilot" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Perry HM, Jr., Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke 1989; 20:4-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry HM, Jr</AU>
<TI>Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>4-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-STOP" NAME="STOP" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) [see comments]. Lancet 1991; 338:1281-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO</AU>
<TI>Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) [see comments]</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>1281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Syst_x002d_eur" NAME="Syst-eur" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators [see comments]. Lancet 1997; 350:757-64.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staessen JA, Fagard R, Thijs L, et al</AU>
<TI>Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators [see comments]</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>757-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Barraclough" NAME="Barraclough" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Barraclough M, Joy M, MacGregor G, et al. Control of Moderately Raised Blood Pressure: Report of a Co-Operative Randomized, Controlled Trial. British Medical Journal 1973; 3:434-436.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barraclough M, Joy M, MacGregor G, et al</AU>
<TI>Control of Moderately Raised Blood Pressure: Report of a Co-Operative Randomized, Controlled Trial</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>3</VL>
<PG>434-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BBB" NAME="BBB" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Hannson L. The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in &amp;quot;well-treated&amp;quot; hypertensive patients. Behandla Blodtryck Battre. Blood Press 1994; 3:248-54.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hannson L</AU>
<TI>The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive patients. Behandla Blodtryck Battre</TI>
<SO>Blood Press</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>248-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Estacio" NAME="Estacio" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension [see comments]. N Engl J Med 1998; 338:645-52.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW</AU>
<TI>The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension [see comments]</TI>
<SO>N Engl J Med</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>645-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FACET" NAME="FACET" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM [see comments]. Diabetes Care 1998; 21:597-603.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tatti P, Pahor M, Byington RP, et al</AU>
<TI>Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM [see comments]</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>597-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HAPPHY" NAME="HAPPHY" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5:561-72.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmsen L, Berglund G, Elmfeldt D, et al</AU>
<TI>Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial</TI>
<SO>J Hypertens</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>561-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOT" NAME="HOT" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments]. Lancet 1998; 351:1755-62.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansson L, Zanchetti A, Carruthers SG, et al</AU>
<TI>Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments]</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>1755-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IPPPSH" NAME="IPPPSH" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Myocardial infarctions and cerebrovascular accidents in relation to blood pressure control. The IPPPSH Collaborative Group. J Hypertens Suppl 1985; 3 Suppl 3:S513-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myocardial infarctions and cerebrovascular accidents in relation to blood pressure control</AU>
<TI>The IPPPSH Collaborative Group</TI>
<SO>J Hypertens Suppl</SO>
<YR>1985</YR>
<VL>3 Suppl 3</VL>
<PG>S513-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-kuramoto" NAME="kuramoto" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J 1981; 22:75-85.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuramoto K, Matsushita S, Kuwajima I, Murakami M</AU>
<TI>Prospective study on the treatment of mild hypertension in the aged</TI>
<SO>Jpn Heart J</SO>
<YR>1981</YR>
<VL>22</VL>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MAPHY" NAME="MAPHY" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. Jama 1988; 259:1976-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G</AU>
<TI>Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study</TI>
<SO>Jama</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>1976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRFIT" NAME="MRFIT" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. Jama 1982; 248:1465-77.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Multiple risk factor intervention trial</AU>
<TI>Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group</TI>
<SO>Jama</SO>
<YR>1982</YR>
<VL>248</VL>
<PG>1465-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslo" NAME="Oslo" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980; 69:725-32.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland A</AU>
<TI>Treatment of mild hypertension: a five year controlled drug trial. The Oslo study</TI>
<SO>Am J Med</SO>
<YR>1980</YR>
<VL>69</VL>
<PG>725-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith" NAME="Smith" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 1977; 40:I98-105.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith WM</AU>
<TI>Treatment of mild hypertension: results of a ten-year intervention trial</TI>
<SO>Circ Res</SO>
<YR>1977</YR>
<VL>40</VL>
<PG>I98-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sprackling" NAME="Sprackling" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Sprackling ME, Mitchell JR, Short AH, Watt G. Blood pressure reduction in elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed) 1981; 283:1151-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sprackling ME, Mitchell JR, Short AH, Watt G</AU>
<TI>Blood pressure reduction in elderly: a randomised controlled trial of methyldopa</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1981</YR>
<VL>283</VL>
<PG>1151-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOMHS" NAME="TOMHS" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Neaton JD, Grimm RH, Jr., Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Jama 1993; 270:713-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neaton JD, Grimm RH, Jr</AU>
<TI>Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results</TI>
<SO>Jama</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>713-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA115_x002d_129" NAME="VA115-129" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm hg. JAMA 1967; 202:116-122.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm hg</TI>
<SO>JAMA</SO>
<YR>1967</YR>
<VL>202</VL>
<PG>116-122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA90_x002d_114" NAME="VA90-114" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment , II: results in patients with diastolic blood pressures averaging 90 through 114 mm hg. JAMA 1970; 213:1143-1152.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>Effects of treatment , II: results in patients with diastolic blood pressures averaging 90 through 114 mm hg</TI>
<SO>JAMA</SO>
<YR>1970</YR>
<VL>213</VL>
<PG>1143-1152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VAfeasibility" NAME="VAfeasibility" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann N Y Acad Sci 1978; 304:267-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial</AU>
<TI>Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension</TI>
<SO>Ann N Y Acad Sci</SO>
<YR>1978</YR>
<VL>304</VL>
<PG>267-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff" NAME="Wolff" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Wolff FW, Lindeman RD. Effects of treatment in hypertension. Results of a controlled study. J Chronic Dis 1966; 19:227-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolff FW, Lindeman RD</AU>
<TI>Effects of treatment in hypertension. Results of a controlled study</TI>
<SO>J Chronic Dis</SO>
<YR>1966</YR>
<VL>19</VL>
<PG>227-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-ALLHAT" NAME="ALLHAT" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis BR, Cutler JA, Gordon DJ, et al</AU>
<TI>Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</TI>
<SO>Am J Hypertens</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>342-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ANBP2" NAME="ANBP2" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Wing LM, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Hypertens 1997; 19:779-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wing LM, Reid CM, Ryan P, et al</AU>
<TI>Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia</TI>
<SO>Clin Exp Hypertens</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>779-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LIFE" NAME="LIFE" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10:705-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof B, Devereux R, de Faire U, et al</AU>
<TI>The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group</TI>
<SO>Am J Hypertens</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>705-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHELL" NAME="SHELL" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Malacco E, Gnemmi AE, Romagnoli A, Coppini A. Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group. J Cardiovasc Pharmacol 1994; 23 Suppl 5:S62-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malacco E, Gnemmi AE, Romagnoli A, Coppini A</AU>
<TI>Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group</TI>
<SO>J Cardiovasc Pharmacol</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>5</NO>
<PG>S62-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOPhtn2" NAME="STOPhtn2" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Lindholm LH, Hansson L, Dahlof B, et al. The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. Blood Press 1996; 5:300-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindholm LH, Hansson L, Dahlof B, et al</AU>
<TI>The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report</TI>
<SO>Blood Press</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>300-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Alderman-1993" NAME="Alderman 1993" NOTES="&lt;p&gt;Alderman, MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med. 1993;119:329-35.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Alderman, MH</AU>
<TI>Blood pressure management: individualized treatment based on absolute risk and the potential for benefit</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amery-1985" NAME="Amery 1985" NOTES="&lt;p&gt;Amery, A, Birkenhager, W, Brixko, P, Bulpitt, C, Clement, D, Deruyttere, M, De Schaepdryver, A, Dollery, C, Fagard, R, Forette, F and et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-54.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Amery, A, Birkenhager, W, Brixko, P, Bulpitt, C, Clement, D, Deruyttere, M, De Schaepdryver, A, Dollery, C, Fagard, R, Forette, F and et al</AU>
<TI>Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>1349-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anastos-1991" NAME="Anastos 1991" NOTES="&lt;p&gt;Anastos, K, Charney, P, Charon, RA, Cohen, E, Jones, CY, Marte, C, Swiderski, DM, Wheat, ME and Williams, S. Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991;115:287-93.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Anastos, K, Charney, P, Charon, RA, Cohen, E, Jones, CY, Marte, C, Swiderski, DM, Wheat, ME and Williams, S</AU>
<TI>Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine</TI>
<SO>Ann Intern Med</SO>
<YR>1991</YR>
<VL>115</VL>
<PG>287-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-1991" NAME="Anderson 1991" NOTES="&lt;p&gt;Anderson, KM, Wilson, PW, Odell, PM and Kannel, WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Anderson, KM, Wilson, PW, Odell, PM and Kannel, WB</AU>
<TI>An updated coronary risk profile. A statement for health professionals</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>83</VL>
<PG>356-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Australian-1980" NAME="Australian 1980" NOTES="&lt;p&gt;The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet. 1980;1:1261-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>The Australian therapeutic trial in mild hypertension</AU>
<TI>Report by the Management Committee</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>1261-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burt-1995" NAME="Burt 1995" NOTES="&lt;p&gt;Burt, VL, Culter, JA, Higgins, M, Horan, MJ, Labarthe, D, Whelton, P, Brown, C and Roccella, EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US Population. Data From the Health Examinination Surveys, 1960 to 1991. Hypertension. 1995;26:60-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Burt, VL, Culter, JA, Higgins, M, Horan, MJ, Labarthe, D, Whelton, P, Brown, C and Roccella, EJ</AU>
<TI>Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US Population. Data From the Health Examinination Surveys, 1960 to 1991</TI>
<SO>Hypertension</SO>
<YR>1995</YR>
<VL>26</VL>
<PG>60-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casiglia-1994" NAME="Casiglia 1994" NOTES="&lt;p&gt;Casiglia, E, Spolaore, P, Mazza, A, Ginocchio, G, Colangeli, G, Onesto, C, Di Menza, G, Pegoraro, L and Ambrosio, GB. Effect of two different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly. Jpn Heart J. 1994;35:589-600.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Casiglia, E, Spolaore, P, Mazza, A, Ginocchio, G, Colangeli, G, Onesto, C, Di Menza, G, Pegoraro, L and Ambrosio, GB</AU>
<TI>Effect of two different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly</TI>
<SO>Jpn Heart J</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>589-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1990" NAME="Collins 1990" NOTES="&lt;p&gt;Collins, R, Peto, R, MacMahon, S, Hebert, P, Fiebach, NH, Eberlein, KA, Godwin, J, Qizilbash, N, Taylor, JO and Hennekens, CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Collins, R, Peto, R, MacMahon, S, Hebert, P, Fiebach, NH, Eberlein, KA, Godwin, J, Qizilbash, N, Taylor, JO and Hennekens, CH</AU>
<TI>Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>827-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" NAME="Cook 1995" NOTES="&lt;p&gt;Cook, RJ and Sackett, DL. The number needed to treat: a clinically useful measure of treatment. Bmj. 1995;310:452-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cook, RJ and Sackett, DL</AU>
<TI>The number needed to treat: a clinically useful measure of treatment</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>452-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coope-1986" NAME="Coope 1986" NOTES="&lt;p&gt;Coope, J and Warrender, TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293:1145-51.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Coope, J, Warrender, TS</AU>
<TI>Randomised trial of treatment of hypertension in elderly patients in primary care</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1986</YR>
<VL>293</VL>
<PG>1145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Croog-1990" NAME="Croog 1990" NOTES="&lt;p&gt;Croog, SH, Kong, BW, Levine, S, Weir, MR, Baume, RM and Saunders, E. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Arch Intern Med. 1990;150:1733-41.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Croog, SH, Kong, BW, Levine, S, Weir, MR, Baume, RM and Saunders, E</AU>
<TI>Hypertensive black men and women. Quality of life and effects of antihypertensive medications</TI>
<SO>Arch Intern Med</SO>
<YR>1990</YR>
<VL>150</VL>
<PG>1733-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dahlof-1991" NAME="Dahlof 1991" NOTES="&lt;p&gt;Dahlof, B, Lindholm, LH, Hansson, L, Schersten, B, Ekbom, T and Wester, PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)b. Lancet. 1991;338:1281-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof, B, Lindholm, LH, Hansson, L, Schersten, B, Ekbom, T and Wester, PO</AU>
<TI>Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)b</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>1281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dahlof-1997" NAME="Dahlof 1997" NOTES="&lt;p&gt;Dahlof, B, Devereux, R, de Faire, U, Fyhrquist, F, Hedner, T, Ibsen, H, Julius, S, Kjeldsen, S, Kristianson, K, Lederballe-Pedersen, O, Lindholm, LH, Nieminen, MS, Omvik, P, Oparil, S and Wedel, H. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705-13.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dahlof, B, Devereux, R, de Faire, U, Fyhrquist, F, Hedner, T, Ibsen, H, Julius, S, Kjeldsen, S, Kristianson, K, Lederballe-Pedersen, O, Lindholm, LH, Nieminen, MS, Omvik, P, Oparil, S and Wedel, H</AU>
<TI>The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group</TI>
<SO>Am J Hypertens</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>705-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1996" NAME="Davis 1996" NOTES="&lt;p&gt;Davis, BR, Cutler, JA, Gordon, DJ, Furberg, CD, Wright, JT, Jr., Cushman, WC, Grimm, RH, LaRosa, J, Whelton, PK, Perry, HM, Alderman, MH, Ford, CE, Oparil, S, Francis, C, Proschan, M, Pressel, S, Black, HR and Hawkins, CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-60.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Davis, BR, Cutler, JA, Gordon, DJ, Furberg, CD, Wright, JT, Jr, Cushman, WC et al</AU>
<TI>Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</TI>
<SO>Am J Hypertens</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>342-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Estacio-1998" NAME="Estacio 1998" NOTES="&lt;p&gt;Estacio, RO, Jeffers, BW, Hiatt, WR, Biggerstaff, SL, Gifford, N and Schrier, RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-52.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Estacio, RO, Jeffers, BW, Hiatt, WR, Biggerstaff, SL, Gifford, N and Schrier, RW</AU>
<TI>The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension</TI>
<SO>N Engl J Med</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>645-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiebach-1989" NAME="Fiebach 1989" NOTES="&lt;p&gt;Fiebach, NH, Hebert, PR, Stampfer, MJ, Colditz, GA, Willett, WC, Rosner, B, Speizer, FE and Hennekens, CH. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol. 1989;130:646-54.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fiebach, NH, Hebert, PR, Stampfer, MJ, Colditz, GA, Willett, WC, Rosner, B, Speizer, FE and Hennekens, CH</AU>
<TI>A prospective study of high blood pressure and cardiovascular disease in women</TI>
<SO>Am J Epidemiol</SO>
<YR>1989</YR>
<VL>130</VL>
<PG>646-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gueyffier-1995" NAME="Gueyffier 1995" NOTES="&lt;p&gt;Gueyffier, F, Boutitie, F, Boissel, JP, Coope, J, Cutler, J, Ekbom, T, Fagard, R, Friedman, L, Perry, HM, Pocock, S and et al. INDANA: a meta-analysis on individual patient data in hypertension. Therapie. 1995;50:353-62.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gueyffier, F, Boutitie, F, Boissel, JP, Coope, J, Cutler, J, Ekbom, T, Fagard, R, Friedman, L, Perry, HM, Pocock, S and et al</AU>
<TI>INDANA: a meta-analysis on individual patient data in hypertension</TI>
<SO>Therapie</SO>
<YR>1995</YR>
<VL>50</VL>
<PG>353-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gueyffier-1997" NAME="Gueyffier 1997" NOTES="&lt;p&gt;Gueyffier, F, Boutitie, F, Boissel, JP, Pocock, S, Coope, J, Cutler, J, Ekbom, T, Fagard, R, Friedman, L, Perry, M, Prineas, R and Schron, E. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med. 1997;126:761-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gueyffier, F, Boutitie, F, Boissel, JP, Pocock, S, Coope, J, Cutler, J, Ekbom, T, Fagard, R, Friedman, L, Perry, M, Prineas, R and Schron, E</AU>
<TI>Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials</TI>
<SO>Ann Intern Med</SO>
<YR>1997</YR>
<VL>126</VL>
<PG>761-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gueyffier-1999" NAME="Gueyffier 1999" NOTES="&lt;p&gt;Gueyffier, F, Bulpitt, Christopher, Boissel, Jean-Pierre, Schron, Eleanor, Ekbom, Tord, Fagard, Robert, Casiglia, Edoardo, Kerlikowske, Karla, Coope, John. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet. 1999;353(9155):793-796.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gueyffier, F, Bulpitt, C, Boissel, JP, Schron, E, Ekbom, T, Fagard, R, Casiglia, E, Kerlikowske, K, Coope, J</AU>
<TI>Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9155</NO>
<PG>793-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hannson-1994" NAME="Hannson 1994" NOTES="&lt;p&gt;Hannson, L. The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in &amp;quot;well-treated&amp;quot; hypertensive patients. Behandla Blodtryck Battre. Blood Press. 1994;3:248-54.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hannson, L</AU>
<TI>The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive patients. Behandla Blodtryck Battre</TI>
<SO>Blood Press</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>248-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansson-1998" NAME="Hansson 1998" NOTES="&lt;p&gt;Hansson, L, Zanchetti, A, Carruthers, SG, Dahlof, B, Elmfeldt, D, Julius, S, Menard, J, Rahn, KH, Wedel, H and Westerling, S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hansson, L, Zanchetti, A, Carruthers, SG, Dahlof, B, Elmfeldt, D, Julius, S, Menard, J, Rahn, KH, Wedel, H and Westerling, S</AU>
<TI>Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>1755-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayes-1998" NAME="Hayes 1998" NOTES="&lt;p&gt;Hayes, SN and Taler, SJ. Hypertension in women: current understanding of gender differences. Mayo Clin Proc. 1998;73:157-65.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hayes, SN and Taler, SJ</AU>
<TI>Hypertension in women: current understanding of gender differences</TI>
<SO>Mayo Clin Proc</SO>
<YR>1998</YR>
<VL>73</VL>
<PG>157-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Helgeland-1980" NAME="Helgeland 1980" NOTES="&lt;p&gt;Helgeland, A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med. 1980;69:725-32.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland, A</AU>
<TI>Treatment of mild hypertension: a five year controlled drug trial. The Oslo study</TI>
<SO>Am J Med</SO>
<YR>1980</YR>
<VL>69</VL>
<PG>725-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Insua-1994" NAME="Insua 1994" NOTES="&lt;p&gt;Insua, JT, Sacks, HS, Lau, TS, Lau, J, Reitman, D, Pagano, D and Chalmers, TC. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med. 1994;121:355-62.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Insua, JT, Sacks, HS, Lau, TS, Lau, J, Reitman, D, Pagano, D and Chalmers, TC</AU>
<TI>Drug treatment of hypertension in the elderly: a meta-analysis</TI>
<SO>Ann Intern Med</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>355-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-1993" NAME="Jackson 1993" NOTES="&lt;p&gt;Jackson, R, Barham, P, Bills, J, Birch, T, McLennan, L, MacMahon, S and Maling, T. Management of raised blood pressure in New Zealand: a discussion document. Bmj. 1993;307:107-10.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jackson, R, Barham, P, Bills, J, Birch, T, McLennan, L, MacMahon, S and Maling, T</AU>
<TI>Management of raised blood pressure in New Zealand: a discussion document</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>107-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johannesson-1993" NAME="Johannesson 1993" NOTES="&lt;p&gt;Johannesson, M, Dahlof, B, Lindholm, LH, Ekbom, T, Hansson, L, Oden, A, Schersten, B, Wester, PO and Jonsson, B. The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med. 1993;234:317-23.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Johannesson, M, Dahlof, B, Lindholm, LH, Ekbom, T, Hansson, L, Oden, A, Schersten, B, Wester, PO and Jonsson, B</AU>
<TI>The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension)</TI>
<SO>J Intern Med</SO>
<YR>1993</YR>
<VL>234</VL>
<PG>317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johannesson-1994" NAME="Johannesson 1994" NOTES="&lt;p&gt;Johannesson, M. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials. Med Decis Making. 1994;14:236-44.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Johannesson, M</AU>
<TI>The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials</TI>
<SO>Med Decis Making</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>236-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kannel-1992" NAME="Kannel 1992" NOTES="&lt;p&gt;Kannel, WB and Wolf, PA. Pulling it all together: changing the cardiovascular outlook [editorial]. Am Heart J. 1992;123:264-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kannel, WB and Wolf, PA</AU>
<TI>Pulling it all together: changing the cardiovascular outlook [editorial]</TI>
<SO>Am Heart J</SO>
<YR>1992</YR>
<VL>123</VL>
<PG>264-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1995" NAME="Kaplan 1995" NOTES="&lt;p&gt;Kaplan, NM. The treatment of hypertension in women. Arch Intern Med. 1995;155:563-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan, NM</AU>
<TI>The treatment of hypertension in women</TI>
<SO>Arch Intern Med</SO>
<YR>1995</YR>
<VL>155</VL>
<PG>563-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuhn-1993" NAME="Kuhn 1993" NOTES="&lt;p&gt;Kuhn, FE and Rackley, CE. Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention. Arch Intern Med. 1993;153:2626-36.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kuhn, FE and Rackley, CE</AU>
<TI>Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention</TI>
<SO>Arch Intern Med</SO>
<YR>1993</YR>
<VL>153</VL>
<PG>2626-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuramoto-1981" NAME="Kuramoto 1981" NOTES="&lt;p&gt;Kuramoto, K, Matsushita, S, Kuwajima, I and Murakami, M. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J. 1981;22:75-85.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kuramoto, K, Matsushita, S, Kuwajima, I and Murakami, M</AU>
<TI>Prospective study on the treatment of mild hypertension in the aged</TI>
<SO>Jpn Heart J</SO>
<YR>1981</YR>
<VL>22</VL>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindholm-1996" NAME="Lindholm 1996" NOTES="&lt;p&gt;Lindholm, LH, Hansson, L, Dahlof, B, Ekbom, T, Hedner, T, De Faire, U, Schersten, B and Wester, PO. The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. Blood Press. 1996;5:300-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lindholm, LH, Hansson, L, Dahlof, B, Ekbom, T, Hedner, T, De Faire, U, Schersten, B and Wester, PO</AU>
<TI>The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report</TI>
<SO>Blood Press</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>300-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacMahon-1993" NAME="MacMahon 1993" NOTES="&lt;p&gt;MacMahon, S and Rodgers, A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens. 1993;15:967-78.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>MacMahon, S and Rodgers, A</AU>
<TI>The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives</TI>
<SO>Clin Exp Hypertens</SO>
<YR>1993</YR>
<VL>15</VL>
<PG>967-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malacco-1994" NAME="Malacco 1994" NOTES="&lt;p&gt;Malacco, E, Gnemmi, AE, Romagnoli, A and Coppini, A. Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group. J Cardiovasc Pharmacol. 1994;23 Suppl 5:S62-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Malacco, E, Gnemmi, AE, Romagnoli, A and Coppini, A</AU>
<TI>Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group</TI>
<SO>J Cardiovasc Pharmacol</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>5</NO>
<PG>S62-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1997" NAME="McQuay 1997" NOTES="&lt;p&gt;McQuay, HJ and Moore, RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712-20.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>McQuay, HJ and Moore, RA</AU>
<TI>Using numerical results from systematic reviews in clinical practice</TI>
<SO>Ann Intern Med</SO>
<YR>1997</YR>
<VL>126</VL>
<PG>712-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-1985" NAME="MRC 1985" NOTES="&lt;p&gt;MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97-104.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party</AU>
<TI>MRC trial of treatment of mild hypertension: principal results</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1985</YR>
<VL>291</VL>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-1992" NAME="MRC 1992" NOTES="&lt;p&gt;Medical Research Council trial of treatment of hypertension in older adults: principal results. Bmj. 1992;304:405-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party</AU>
<TI>Medical Research Council trial of treatment of hypertension in older adults: principal results</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<PG>405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1994" NAME="Mulrow 1994" NOTES="&lt;p&gt;Mulrow, CD, Cornell, JA, Herrera, CR, Kadri, A, Farnett, L and Aguilar, C. Hypertension in the elderly. Implications and generalizability of Randomized Trials. Jama. 1994;272:1932-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mulrow, CD, Cornell, JA, Herrera, CR, Kadri, A, Farnett, L and Aguilar, C</AU>
<TI>Hypertension in the elderly. Implications and generalizability of Randomized Trials</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>1932-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neaton-1993" NAME="Neaton 1993" NOTES="&lt;p&gt;Neaton, JD, Grimm, RH, Jr., Prineas, RJ, Stamler, J, Grandits, GA, Elmer, PJ, Cutler, JA, Flack, JM, Schoenberger, JA, McDonald, R and et al. Treatment of Mild Hypertension Study. Final results. Jama. 1993;270:713-24.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Neaton, JD, Grimm, RH, Jr, Prineas, RJ, Stamler, J, Grandits, GA, Elmer, PJ et al</AU>
<TI>Treatment of Mild Hypertension Study. Final results</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>713-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nielsen-1995" NAME="Nielsen 1995" NOTES="&lt;p&gt;Nielsen, WB, Vestbo, J and Jensen, GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens. 1995;9:175-80.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen, WB, Vestbo, J and Jensen, GB</AU>
<TI>Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study</TI>
<SO>J Hum Hypertens</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perlman-1988" NAME="Perlman 1988" NOTES="&lt;p&gt;Perlman, JA, Wolf, PH, Ray, R and Lieberknecht, G. Cardiovascular risk factors, premature heart disease, and all-cause mortality in a cohort of northern California women. Am J Obstet Gynecol. 1988;158:1568-74.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Perlman, JA, Wolf, PH, Ray, R and Lieberknecht, G</AU>
<TI>Cardiovascular risk factors, premature heart disease, and all-cause mortality in a cohort of northern California women</TI>
<SO>Am J Obstet Gynecol</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>1568-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perry-1989" NAME="Perry 1989" NOTES="&lt;p&gt;Perry, HM, Jr., Smith, WM, McDonald, RH, Black, D, Cutler, JA, Furberg, CD, Greenlick, MR, Kuller, LH, Schnaper, HW, Schoenberger, JA and et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke. 1989;20:4-13.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Perry, HM, Jr, Smith, WM, McDonald, RH, Black, D, Cutler, JA, Furberg, CD et al</AU>
<TI>Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>4-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Psaty-1997" NAME="Psaty 1997" NOTES="&lt;p&gt;Psaty, BM, Smith, NL, Siscovick, DS, Koepsell, TD, Weiss, NS, Heckbert, SR, Lemaitre, RN, Wagner, EH and Furberg, CD. Health outcomes associated with antihypertensive therapies used as first line agents. Jama. 1997;277:739-45.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Psaty, BM, Smith, NL, Siscovick, DS, Koepsell, TD, Weiss, NS, Heckbert, SR, Lemaitre, RN, Wagner, EH and Furberg, CD</AU>
<TI>Health outcomes associated with antihypertensive therapies used as first line agents</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>277</VL>
<PG>739-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajkumar-1996" NAME="Rajkumar 1996" NOTES="&lt;p&gt;Rajkumar, SV, Sampathkumar, P and Gustafson, AB. Number needed to treat is a simple measure of treatment efficacy for clinicians. J Gen Intern Med. 1996;11:357-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rajkumar, SV, Sampathkumar, P and Gustafson, AB</AU>
<TI>Number needed to treat is a simple measure of treatment efficacy for clinicians</TI>
<SO>J Gen Intern Med</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>357-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Report-1986" NAME="Report 1986" NOTES="&lt;p&gt;Report of the Task Force on Black and Minority Health. Cardiovascular and Cerebrovascular Disease, Part 2. US Department of Health and Human Services. Washington, DC: US Government Printing Office. 1986;IV:I-1-I-21.&lt;/p&gt;" TYPE="BOOK">
<AU>Report of the Task Force on Black and Minority Health</AU>
<SO>Cardiovascular and Cerebrovascular Disease, Part 2. US Department of Health and Human Services</SO>
<YR>1986</YR>
<VL>IV</VL>
<PG>I-1-I-21</PG>
<PB>US Government Printing Office</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schnall-1984" NAME="Schnall 1984" NOTES="&lt;p&gt;Schnall, PL, Alderman, MH and Kern, R. An analysis of the HDFP trial. Evidence of adverse effects of antihypertensive treatment on white women with moderate and severe hypertension. N Y State J Med. 1984;84:299-301.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Schnall, PL, Alderman, MH and Kern, R</AU>
<TI>An analysis of the HDFP trial. Evidence of adverse effects of antihypertensive treatment on white women with moderate and severe hypertension</TI>
<SO>N Y State J Med</SO>
<YR>1984</YR>
<VL>84</VL>
<PG>299-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sigurdsson-1984" NAME="Sigurdsson 1984" NOTES="&lt;p&gt;Sigurdsson, JA, Bengtsson, C, Lapidus, L, Lindquist, O and Rafnsson, V. Morbidity and mortality in relation to blood pressure and antihypertensive treatment. A 12-year follow-up study of a population sample of Swedish women. Acta Med Scand. 1984;215:313-22.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sigurdsson, JA, Bengtsson, C, Lapidus, L, Lindquist, O and Rafnsson, V</AU>
<TI>Morbidity and mortality in relation to blood pressure and antihypertensive treatment. A 12-year follow-up study of a population sample of Swedish women</TI>
<SO>Acta Med Scand</SO>
<YR>1984</YR>
<VL>215</VL>
<PG>313-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sinclair-1994" NAME="Sinclair 1994" NOTES="&lt;p&gt;Sinclair, JC and Bracken, MB. Clinically useful measures of effect in binary analyses of randomized trials. J Clin Epidemiol. 1994;47:881-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sinclair, JC and Bracken, MB</AU>
<TI>Clinically useful measures of effect in binary analyses of randomized trials</TI>
<SO>J Clin Epidemiol</SO>
<YR>1994</YR>
<VL>47</VL>
<PG>881-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sixth-report-1997" NAME="Sixth report 1997" NOTES="&lt;p&gt;The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure</AU>
<TI>The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure</TI>
<SO>Arch Intern Med</SO>
<YR>1997</YR>
<VL>157</VL>
<PG>2413-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1977" NAME="Smith 1977" NOTES="&lt;p&gt;Smith, WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40:I98-105.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Smith, WM</AU>
<TI>Treatment of mild hypertension: results of a ten-year intervention trial</TI>
<SO>Circ Res</SO>
<YR>1977</YR>
<VL>40</VL>
<PG>I98-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sprackling-1981" NAME="Sprackling 1981" NOTES="&lt;p&gt;Sprackling, ME, Mitchell, JR, Short, AH and Watt, G. Blood pressure reduction in elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed). 1981;283:1151-3.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sprackling, ME, Mitchell, JR, Short, AH and Watt, G</AU>
<TI>Blood pressure reduction in elderly: a randomised controlled trial of methyldopa</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1981</YR>
<VL>283</VL>
<PG>1151-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staessen-1997" NAME="Staessen 1997" NOTES="&lt;p&gt;Staessen, JA, Fagard, R, Thijs, L, Celis, H, Arabidze, GG, Birkenhager, WH, Bulpitt, CJ, de Leeuw, PW, Dollery, CT, Fletcher, AE, Forette, F, Leonetti, G, Nachev, C, ET, OB, Rosenfeld, J, Rodicio, JL, Tuomilehto, J and Zanchetti, A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-64.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Staessen, JA, Fagard, R, Thijs, L, Celis, H, Arabidze, GG, Birkenhager, WH, Bulpitt, CJ, de Leeuw, PW, Dollery, CT, Fletcher, AE, Forette, F, Leonetti, G, Nachev, C, ET, OB, Rosenfeld, J, Rodicio, JL, Tuomilehto, J and Zanchetti, A</AU>
<TI>Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>757-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staessen-1998" NAME="Staessen 1998" NOTES="&lt;p&gt;Staessen, JA, Fagard, R, Thijs, L, Celis, H, Birkenhager, WH, Bulpitt, CJ, de Leeuw, PW, Fletcher, AE, Babarskiene, MR, Forette, F, Kocemba, J, Laks, T, Leonetti, G, Nachev, C, Petrie, JC, Tuomilehto, J, Vanhanen, H, Webster, J, Yodfat, Y and Zanchetti, A. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med. 1998;158:1681-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Staessen, JA, Fagard, R, Thijs, L, Celis, H, Birkenhager, WH, Bulpitt, CJ et al</AU>
<TI>Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly</TI>
<SO>Arch Intern Med</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>1681-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanford-1987" NAME="Stanford 1987" NOTES="&lt;p&gt;Stanford, JL, Hartge, P, Brinton, LA, Hoover, RN and Brookmeyer, R. Factors influencing the age at natural menopause. J Chronic Dis. 1987;40:995-1002.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stanford, JL, Hartge, P, Brinton, LA, Hoover, RN and Brookmeyer, R</AU>
<TI>Factors influencing the age at natural menopause</TI>
<SO>J Chron Dis</SO>
<YR>1987</YR>
<VL>40</VL>
<PG>995-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tatti-1998" NAME="Tatti 1998" NOTES="&lt;p&gt;Tatti, P, Pahor, M, Byington, RP, Di Mauro, P, Guarisco, R, Strollo, G and Strollo, F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tatti, P, Pahor, M, Byington, RP, Di Mauro, P, Guarisco, R, Strollo, G and Strollo, F</AU>
<TI>Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>597-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-US-Dept-1991" NAME="US Dept 1991" NOTES="&lt;p&gt;U.S. Department of Commerce, Economics, and Statistics Administration and Bureau of the Census. Vital statistics: statistical abstract of the United States. Washington, D.C.: U.S. Government Printing Office. 1991;11th ed.:84.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>US Department of Commerce, Economics, and Statistics Administration and Bureau of the Census</AU>
<TI>Vital statistics: statistical abstract of the United States</TI>
<SO>Vital statistics: statistical abstract of the United States</SO>
<YR>1991</YR>
<PG>84</PG>
<EN>11th</EN>
<PB>Government Printing Office</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-VA_x002d_NHLBI-1978" NAME="VA-NHLBI 1978" NOTES="&lt;p&gt;Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann N Y Acad Sci. 1978;304:267-92.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial</AU>
<TI>Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension</TI>
<SO>Ann N Y Acad Sci</SO>
<YR>1978</YR>
<VL>304</VL>
<PG>267-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Veterans-1967" NAME="Veterans 1967" NOTES="&lt;p&gt;Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm hg. JAMA. 1967;202:116-122.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm hg</TI>
<SO>JAMA</SO>
<YR>1967</YR>
<VL>202</VL>
<PG>116-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Veterans-1970" NAME="Veterans 1970" NOTES="&lt;p&gt;Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment , II: results in patients with diastolic blood pressures averaging 90 through 114 mm hg. JAMA. 1970;213:1143-1152.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Administration Cooperative Study Group on Antihypertensive Agents</AU>
<TI>Effects of treatment , II: results in patients with diastolic blood pressures averaging 90 through 114 mm hg</TI>
<SO>JAMA</SO>
<YR>1970</YR>
<VL>213</VL>
<PG>1143-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wenger-1993" NAME="Wenger 1993" NOTES="&lt;p&gt;Wenger, NK, Speroff, L and Packard, B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-56.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wenger, NK, Speroff, L and Packard, B</AU>
<TI>Cardiovascular health and disease in women</TI>
<SO>N Engl J Med</SO>
<YR>1993</YR>
<VL>329</VL>
<PG>247-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whelan-1990" NAME="Whelan 1990" NOTES="&lt;p&gt;Whelan, EA, Sandler, DP, McConnaughey, DR and Weinberg, CR. Menstrual and reproductive characteristics and age at natural menopause. Am J Epidemiol. 1990;131:625-32.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Whelan, EA, Sandler, DP, McConnaughey, DR and Weinberg, CR</AU>
<TI>Menstrual and reproductive characteristics and age at natural menopause</TI>
<SO>Am J Epidemiol</SO>
<YR>1990</YR>
<VL>131</VL>
<PG>625-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wikstrand-1998" NAME="Wikstrand 1998" NOTES="&lt;p&gt;Wikstrand, J, Warnold, I, Olsson, G, Tuomilehto, J, Elmfeldt, D and Berglund, G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. Jama. 1988;259:1976-82.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wikstrand, J, Warnold, I, Olsson, G, Tuomilehto, J, Elmfeldt, D and Berglund, G</AU>
<TI>Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>1976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmsen-1987" NAME="Wilhelmsen 1987" NOTES="&lt;p&gt;Wilhelmsen, L, Berglund, G, Elmfeldt, D, Fitzsimons, T, Holzgreve, H, Hosie, J, Hornkvist, PE, Pennert, K, Tuomilehto, J and Wedel, H. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561-72.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmsen, L, Berglund, G, Elmfeldt, D, Fitzsimons, T, Holzgreve, H, Hosie, J, Hornkvist, PE, Pennert, K, Tuomilehto, J and Wedel, H</AU>
<TI>Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial</TI>
<SO>J Hypertens</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>561-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wing-1997" NAME="Wing 1997" NOTES="&lt;p&gt;Wing, LM, Reid, CM, Ryan, P, Beilin, LJ, Brown, MA, Jennings, GL, Johnston, CI, McNeil, JJ, Marley, JE, Morgan, TO, Shaw, J, Steven, ID and West, MJ. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Hypertens. 1997;19:779-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wing, LM, Reid, CM, Ryan, P, Beilin, LJ, Brown, MA, Jennings, GL et al</AU>
<TI>Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia</TI>
<SO>Clin Exp Hypertens</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>779-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolff-1966" NAME="Wolff 1966" NOTES="&lt;p&gt;Wolff, FW and Lindeman, RD. Effects of treatment in hypertension. Results of a controlled study. J Chronic Dis. 1966;19:227-40.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wolff, FW and Lindeman, RD</AU>
<TI>Effects of treatment in hypertension. Results of a controlled study</TI>
<SO>J Chronic Dis</SO>
<YR>1966</YR>
<VL>19</VL>
<PG>227-40</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Saunders-1985" NAME="Saunders 1985" NOTES="&lt;p&gt;Saunders, E, Shulman NB, Ed. Hypertension in Blacks: Epidemiology, Pathophysiology and Treatment. Chicago, Ill: Year Book Medical Publishers. 1985:17-36.&lt;/p&gt;" TYPE="BOOK">
<AU>Saunders, E, Shulman NB, Ed</AU>
<SO>Hypertension in Blacks: Epidemiology, Pathophysiology and Treatment.</SO>
<YR>1985</YR>
<PG>17-36</PG>
<PB>Ill: Year Book Medical Publishers</PB>
<CY>Chicago</CY>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES>
<REFERENCE ID="REF-Five_x002d_year-1979" NAME="Five-year 1979" NOTES="&lt;p&gt;Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. Jama. 1979;242:2562-71.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Five-year findings of the hypertension detection and follow-up program</AU>
<TI>Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>242</VL>
<PG>2562-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Five_x002d_year-1979a" NAME="Five-year 1979a" NOTES="&lt;p&gt;Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group. Jama. 1979;242:2572-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Five-year findings of the hypertension detection and follow-up program</AU>
<TI>II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>242</VL>
<PG>2572-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lever-1995" NAME="Lever 1995" NOTES="&lt;p&gt;Lever, AF and Ramsay, LE. Treatment of hypertension in the elderly. J Hypertens. 1995;13:571-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lever, AF and Ramsay, LE</AU>
<TI>Treatment of hypertension in the elderly</TI>
<SO>J Hypertens</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>571-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Multiple-1982" NAME="Multiple 1982" NOTES="&lt;p&gt;Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. Jama. 1982;248:1465-77.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Multiple Risk Factor Intervention Trial Research Group</AU>
<TI>Risk factor changes and mortality results</TI>
<SO>JAMA</SO>
<YR>1982</YR>
<VL>248</VL>
<PG>1465-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myocardial-1985" NAME="Myocardial 1985" NOTES="&lt;p&gt;Myocardial infarctions and cerebrovascular accidents in relation to blood pressure control. The IPPPSH Collaborative Group. J Hypertens Suppl. 1985;3 Suppl 3:S513-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Myocardial infarctions and cerebrovascular accidents in relation to blood pressure control</AU>
<TI>The IPPPSH Collaborative Group</TI>
<SO>J Hypertens Suppl</SO>
<YR>1985</YR>
<VL>3</VL>
<NO>3</NO>
<PG>S513-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prevention-1991" NAME="Prevention 1991" NOTES="&lt;p&gt;Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. Jama. 1991;265:3255-64.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension</AU>
<TI>Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<PG>3255-64</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Australian">
<CHAR_METHODS>
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>community, primary htn<BR/>1456 white women<BR/> mean age 50.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chlorothiazide vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV M&amp;M</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2.9 yrs f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CASTEL">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>424 white women<BR/> mean age 74 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>clonidine or nifedipine vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV m&amp;m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>12 yrs f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Coope">
<CHAR_METHODS>
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>611 women<BR/>mean age 68 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>atenolol vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV m&amp;m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4.5 yr f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-EWPHE">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>community, primary htn<BR/>586 women<BR/>mean age 72 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>HCTZ/triamterene (maxide) vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV M&amp;M</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4.6 yrs f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HDFP">
<CHAR_METHODS>
<P>RCT of Stepped care vs Usual care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>5030 total women<BR/>2726 black women<BR/>mean age 52.3<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chlorthalidone first step<BR/>vs usual care in community, htn rx allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary:all cause mortality<BR/>secondary other cv M&amp;M</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>F/u 4.9 yrs <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MRC">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>primary htn, community centers<BR/>N women 8306,<BR/>mean age 51 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>bendrufluazide or propranolol vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV M&amp;M</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>5 yrs f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MRC-elderly">
<CHAR_METHODS>
<P>RCT,</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>British, community centers, primary htn<BR/> 2560 white wom<BR/> mean age 70 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hctz/amiloride or atenolol vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV mortality and morbidity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>f/u 5.9 yrs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shep">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1019 women total<BR/>444 African American women<BR/> mean age 75 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>chlortalidone vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV m&amp;m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4.4 yrs f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shep-Pilot">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>349 women total<BR/>African American women n = 67<BR/> mean age 72 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>chlorthalidone vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV m&amp;m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>f/u 2.8 yrs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-STOP">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1019 women<BR/> mean age 72</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>hctz/amiloride, metoprolol, pindolol, or atenolol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV m&amp;m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>f/u 2.2 yrs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Syst_x002d_eur">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>3138 women<BR/>mean age 70.5 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>nitrendipine vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CV m&amp;m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 yrs f/u</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Barraclough">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fewer than 100 women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-BBB">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared two treatment groups, no placebo or usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Estacio">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared two treatment groups, nisoldipine vs enalapril in NIDDM and htn, no placebo or usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-FACET">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared two treatment groups, fosinopril vs amlodipine in NIDDM and htn, no placebo or usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-HAPPHY">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-HOT">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared two treatment groups, no placebo or usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-IPPPSH">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared two treatment groups, no placebo or usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-kuramoto">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fewer than 100 women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MAPHY">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRFIT">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oslo">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fewer than 100 women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sprackling">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fewer than 100 women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TOMHS">
<CHAR_REASON_FOR_EXCLUSION>
<P>Contacted authors, declined to contribute data on women (JDN, RHG)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-VA115_x002d_129">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-VA90_x002d_114">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-VAfeasibility">
<CHAR_REASON_FOR_EXCLUSION>
<P>No women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolff">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fewer than 100 women included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-ALLHAT">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-ANBP2">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-LIFE">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-SHELL">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-STOPhtn2">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Australian">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-CASTEL">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Coope">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EWPHE">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-HDFP">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-MRC">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-MRC-elderly">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-STOP">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shep">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shep-Pilot">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Syst_x002d_eur">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Women ages 30-54 years: Hypertension Treatment versus Placebo or Usual Care</NAME>
<DICH_OUTCOME CHI2="0.6525938293294011" CI_END="1.0764719482691085" CI_START="0.2375542729566916" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5056881559116659" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.03200271704787852" LOG_CI_START="-0.624237153395385" LOG_EFFECT_SIZE="-0.29611721817375325" METHOD="PETO" NO="1" P_CHI2="0.721590963469227" P_Q="1.0" P_Z="0.07692698131902487" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4304" TOTAL_2="4254" WEIGHT="100.0" Z="1.768801650014722">
<NAME>Fatal Cerebrovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.620565732194022" CI_START="0.04960464336434767" EFFECT_SIZE="0.47874995069139215" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6646951528999216" LOG_CI_START="-1.3044776684064376" LOG_EFFECT_SIZE="-0.319891257753258" ORDER="1856" O_E="-0.5505226480836236" SE="1.1567018627980274" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.7474069466752987" WEIGHT="11.105997200471757"/>
<DICH_DATA CI_END="1.2310957155878388" CI_START="0.08992140769038448" EFFECT_SIZE="0.33271888997659826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.09029181989771674" LOG_CI_START="-1.0461369029829666" LOG_EFFECT_SIZE="-0.4779225415426248" ORDER="1857" O_E="-2.469525959367946" SE="0.667543857233017" STUDY_ID="STD-HDFP" TOTAL_1="1540" TOTAL_2="1561" VAR="2.2440906294324243" WEIGHT="33.34577549612852"/>
<DICH_DATA CI_END="1.81143377336203" CI_START="0.23852077423515927" EFFECT_SIZE="0.6573161994793886" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.25802246070608376" LOG_CI_START="-0.6224737896100833" LOG_EFFECT_SIZE="-0.18222566445199975" ORDER="1858" O_E="-1.568537859007833" SE="0.517207855962449" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="3.7382623291401424" WEIGHT="55.54822730339973"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06547282348900929" CI_END="0.9148543762765222" CI_START="0.37849094105289693" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5884420904415845" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.03864803010047348" LOG_CI_START="-0.42194451060993293" LOG_EFFECT_SIZE="-0.23029627035520328" METHOD="PETO" NO="2" P_CHI2="0.9677936253096072" P_Q="1.0" P_Z="0.018512099133109274" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4186" TOTAL_2="4083" WEIGHT="100.0" Z="2.355212837175833">
<NAME>Fatal and Non-Fatal Cerebrovascular Accidents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.620565732194022" CI_START="0.04960464336434767" EFFECT_SIZE="0.47874995069139215" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6646951528999216" LOG_CI_START="-1.3044776684064376" LOG_EFFECT_SIZE="-0.319891257753258" ORDER="1859" O_E="-0.5505226480836236" SE="1.1567018627980274" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.7474069466752987" WEIGHT="3.788802760018749"/>
<DICH_DATA CI_END="1.0568789335457487" CI_START="0.35276892904692253" EFFECT_SIZE="0.6106013834894147" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" LOG_CI_END="0.024025241324108073" LOG_CI_START="-0.45250967336365033" LOG_EFFECT_SIZE="-0.21424221601977117" ORDER="1860" O_E="-6.295874822190612" SE="0.27991896777346065" STUDY_ID="STD-HDFP" TOTAL_1="1422" TOTAL_2="1390" VAR="12.762487920581771" WEIGHT="64.69641428046984"/>
<DICH_DATA CI_END="1.2271719912605545" CI_START="0.25475947169815777" EFFECT_SIZE="0.5591365559291533" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.08890543446360843" LOG_CI_START="-0.5938696603940572" LOG_EFFECT_SIZE="-0.2524821129652243" ORDER="1861" O_E="-3.6142297650130555" SE="0.40106547051062086" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="6.216836610092261" WEIGHT="31.51478295951141"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15341539316302955" CI_END="2.484163865465781" CI_START="0.7680955986289463" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3813309999190404" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3951802402647349" LOG_CI_START="-0.11458472349294112" LOG_EFFECT_SIZE="0.14029775838589686" METHOD="PETO" NO="3" P_CHI2="0.6952927936958007" P_Q="1.0" P_Z="0.28065708774588316" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4304" TOTAL_2="4261" WEIGHT="100.00000000000001" Z="1.0788444600864144">
<NAME>Fatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1862" O_E="0.0" SE="0.0" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.539432431142347" CI_START="0.6571545470136986" EFFECT_SIZE="1.2918202541217738" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.4047366616724233" LOG_CI_START="-0.18233248276557035" LOG_EFFECT_SIZE="0.11120208945342644" ORDER="1863" O_E="2.153153153153152" SE="0.3448473214820104" STUDY_ID="STD-HDFP" TOTAL_1="1540" TOTAL_2="1568" VAR="8.40903743538596" WEIGHT="75.39828298075972"/>
<DICH_DATA CI_END="5.537881533535152" CI_START="0.5195102998004097" EFFECT_SIZE="1.696168180265742" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.743343661073284" LOG_CI_START="-0.284405837708074" LOG_EFFECT_SIZE="0.22946891168260486" ORDER="1864" O_E="1.4497389033942563" SE="0.6037051430262379" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="2.7437860812076416" WEIGHT="24.601717019240294"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.158881483179935" CI_END="1.1408350674224574" CI_START="0.5613948752479315" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8002867988128357" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="69" I2="53.67971758565249" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.05722286222202509" LOG_CI_START="-0.2507315561862661" LOG_EFFECT_SIZE="-0.09675434698212047" METHOD="PETO" NO="4" P_CHI2="0.14174790963491202" P_Q="1.0" P_Z="0.21810656307387555" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4207" TOTAL_2="4097" WEIGHT="100.0" Z="1.2315785979808642">
<NAME>Fatal and Nonfatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1865" O_E="0.0" SE="0.0" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0423766060484259" CI_START="0.4728466153904346" EFFECT_SIZE="0.7020571558870166" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="59" LOG_CI_END="0.018024655987254577" LOG_CI_START="-0.3252797152721231" LOG_EFFECT_SIZE="-0.15362752964243423" ORDER="1866" O_E="-8.698630136986303" SE="0.2016586870618035" STUDY_ID="STD-HDFP" TOTAL_1="1443" TOTAL_2="1404" VAR="24.59043035713179" WEIGHT="80.4663334379811"/>
<DICH_DATA CI_END="3.061372957871303" CI_START="0.6153724392977404" EFFECT_SIZE="1.3725467367945627" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4859162416125955" LOG_CI_START="-0.21086195841183464" LOG_EFFECT_SIZE="0.13752714160038043" ORDER="1867" O_E="1.8903394255874666" SE="0.40929096380206687" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="5.969468803782137" WEIGHT="19.533666562018894"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.37111644669819654" CI_END="1.4333382907024212" CI_START="0.6089416285326077" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9342480147040596" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.15634870292107514" LOG_CI_START="-0.215424335644892" LOG_EFFECT_SIZE="-0.029537816361908394" METHOD="PETO" NO="5" P_CHI2="0.8306405198743583" P_Q="1.0" P_Z="0.7554638651399149" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4304" TOTAL_2="4261" WEIGHT="100.0" Z="0.31144300552083165">
<NAME>Fatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.620565732194022" CI_START="0.04960464336434767" EFFECT_SIZE="0.47874995069139215" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6646951528999216" LOG_CI_START="-1.3044776684064376" LOG_EFFECT_SIZE="-0.319891257753258" ORDER="1868" O_E="-0.5505226480836236" SE="1.1567018627980274" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.7474069466752987" WEIGHT="3.564413797253824"/>
<DICH_DATA CI_END="1.672913960088406" CI_START="0.5758487516453721" EFFECT_SIZE="0.9815016125952236" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.22347360526620946" LOG_CI_START="-0.23969157031187346" LOG_EFFECT_SIZE="-0.00810898252283201" ORDER="1869" O_E="-0.25225225225225145" SE="0.27206551683916125" STUDY_ID="STD-HDFP" TOTAL_1="1540" TOTAL_2="1568" VAR="13.50992691035663" WEIGHT="64.42938494668046"/>
<DICH_DATA CI_END="1.9419281203183916" CI_START="0.4276502494915276" EFFECT_SIZE="0.9112990975243932" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.28823315063541666" LOG_CI_START="-0.3689112702670063" LOG_EFFECT_SIZE="-0.04033905981579477" ORDER="1870" O_E="-0.6233681462140996" SE="0.3860098857554291" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="6.711245808189119" WEIGHT="32.006201256065715"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6189513345557115" CI_END="0.9546853870686235" CI_START="0.5489969428713652" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7239608821646653" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="120" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.020139724930678057" LOG_CI_START="-0.26043007394297407" LOG_EFFECT_SIZE="-0.14028489943682607" METHOD="PETO" NO="6" P_CHI2="0.7338316684750273" P_Q="1.0" P_Z="0.02210787853725037" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4211" TOTAL_2="4106" WEIGHT="100.0" Z="2.288509310516942">
<NAME>Fatal and Nonfatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.620565732194022" CI_START="0.04960464336434767" EFFECT_SIZE="0.47874995069139215" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6646951528999216" LOG_CI_START="-1.3044776684064376" LOG_EFFECT_SIZE="-0.319891257753258" ORDER="1871" O_E="-0.5505226480836236" SE="1.1567018627980274" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.7474069466752987" WEIGHT="1.4890352895403012"/>
<DICH_DATA CI_END="0.9487214409339352" CI_START="0.4994462773161768" EFFECT_SIZE="0.6883570235600804" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="92" LOG_CI_END="-0.022861284331225692" LOG_CI_START="-0.3015112195899729" LOG_EFFECT_SIZE="-0.16218625196059924" ORDER="1872" O_E="-13.939160839160834" SE="0.16368035131041334" STUDY_ID="STD-HDFP" TOTAL_1="1447" TOTAL_2="1413" VAR="37.32560905519974" WEIGHT="74.3626338155017"/>
<DICH_DATA CI_END="1.5230852084638609" CI_START="0.49401748102908083" EFFECT_SIZE="0.8674276442896947" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.18272420046704407" LOG_CI_START="-0.3062576831003519" LOG_EFFECT_SIZE="-0.06176674131665391" ORDER="1873" O_E="-1.7238903394255871" SE="0.2872303789068494" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="12.121022509196116" WEIGHT="24.148330894958008"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3528305377200502" CI_END="1.2163043213525473" CI_START="0.6778242790844325" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9079871143182981" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="97" I2="40.34890885478468" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.08504224973013406" LOG_CI_START="-0.16888287916410372" LOG_EFFECT_SIZE="-0.04192031471698486" METHOD="PETO" NO="7" P_CHI2="0.18704349608970272" P_Q="1.0" P_Z="0.517542601579662" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4304" TOTAL_2="4261" WEIGHT="100.0" Z="0.6471380554076323">
<NAME>All Cause Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.620565732194022" CI_START="0.04960464336434767" EFFECT_SIZE="0.47874995069139215" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6646951528999216" LOG_CI_START="-1.3044776684064376" LOG_EFFECT_SIZE="-0.319891257753258" ORDER="1874" O_E="-0.5505226480836236" SE="1.1567018627980274" STUDY_ID="STD-Australian" TOTAL_1="445" TOTAL_2="416" VAR="0.7474069466752987" WEIGHT="1.6628140950700836"/>
<DICH_DATA CI_END="1.0878620163678776" CI_START="0.5165005317283121" EFFECT_SIZE="0.7495874264560756" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="66" LOG_CI_END="0.03657381325708894" LOG_CI_START="-0.2869292270455166" LOG_EFFECT_SIZE="-0.12517770689421384" ORDER="1875" O_E="-7.981981981981981" SE="0.19002728723962645" STUDY_ID="STD-HDFP" TOTAL_1="1540" TOTAL_2="1568" VAR="27.692876115357176" WEIGHT="61.61048534868726"/>
<DICH_DATA CI_END="2.0884919516598393" CI_START="0.7958516648335534" EFFECT_SIZE="1.2892361291555399" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="29" LOG_CI_END="0.3198328059806203" LOG_CI_START="-0.09916787088980433" LOG_EFFECT_SIZE="0.11033246754540793" ORDER="1876" O_E="4.193864229765012" SE="0.24612307168048841" STUDY_ID="STD-MRC" TOTAL_1="2319" TOTAL_2="2277" VAR="16.50803370357669" WEIGHT="36.72670055624265"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Women &gt; 55 Years : Hypertension Treatment versus Placebo or Usual Care</NAME>
<DICH_OUTCOME CHI2="9.156875995394675" CI_END="0.9955584622100591" CI_START="0.5623266917655416" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.748217278946278" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.001933231799574681" LOG_CI_START="-0.25001130149617445" LOG_EFFECT_SIZE="-0.12597226664787464" METHOD="PETO" NO="1" P_CHI2="0.5172831938654086" P_Q="1.0" P_Z="0.04653463587328507" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8969" TOTAL_2="8635" WEIGHT="99.99999999999996" Z="1.990511341713286">
<NAME>Fatal Cerebrovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.706768428136317" CI_START="0.0026398965855945864" EFFECT_SIZE="0.1330607946534614" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8265133112431724" LOG_CI_START="-2.5784130857003578" LOG_EFFECT_SIZE="-0.8759498872285929" ORDER="1877" O_E="-0.5042016806722689" SE="2.000070620222123" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.24998234587952825" WEIGHT="0.5308371284928812"/>
<DICH_DATA CI_END="2.009494487409968" CI_START="0.25412361628333985" EFFECT_SIZE="0.7146047901057321" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3030868191417806" LOG_CI_START="-0.594954973104111" LOG_EFFECT_SIZE="-0.14593407698116517" ORDER="1878" O_E="-1.2075471698113205" SE="0.5275141941438024" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="3.5936162638328164" WEIGHT="7.631038630694557"/>
<DICH_DATA CI_END="2.0060862672089743" CI_START="0.1443628814654563" EFFECT_SIZE="0.5381490444129479" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3023496049392639" LOG_CI_START="-0.8405444580612804" LOG_EFFECT_SIZE="-0.2690974265610082" ORDER="1879" O_E="-1.3747954173486088" SE="0.6713416300233732" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="2.218772847926197" WEIGHT="4.711560743328349"/>
<DICH_DATA CI_END="1.609711591963711" CI_START="0.43246818797849096" EFFECT_SIZE="0.8343554730116642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.20674807153572994" LOG_CI_START="-0.364045833386511" LOG_EFFECT_SIZE="-0.07864888092539057" ORDER="1880" O_E="-1.6109215017064855" SE="0.33528716522672236" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="8.895413523227475" WEIGHT="18.889396988467556"/>
<DICH_DATA CI_END="1.139855455156777" CI_START="0.2693361420603025" EFFECT_SIZE="0.5540796610581519" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.05684978203131867" LOG_CI_START="-0.5697053649539988" LOG_EFFECT_SIZE="-0.25642779146134004" ORDER="1881" O_E="-4.359001040582726" SE="0.36804159483717336" STUDY_ID="STD-HDFP" TOTAL_1="984" TOTAL_2="938" VAR="7.3825465163007475" WEIGHT="15.67682621702745"/>
<DICH_DATA CI_END="3.9062106373022787" CI_START="0.3662519180007787" EFFECT_SIZE="1.1961008059636962" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5917556583454827" LOG_CI_START="-0.4362200923034357" LOG_EFFECT_SIZE="0.07776778302102345" ORDER="1882" O_E="0.4911051212938009" SE="0.6038380444932078" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="2.7425784293563633" WEIGHT="5.823861093005579"/>
<DICH_DATA CI_END="2.087660285089157" CI_START="0.5498852463980316" EFFECT_SIZE="1.0714352944819558" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.3196598294286511" LOG_CI_START="-0.2597279324255563" LOG_EFFECT_SIZE="0.029965948501547317" ORDER="1883" O_E="0.595703125" SE="0.34033523932883736" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="8.633485438535809" WEIGHT="18.33319310190842"/>
<DICH_DATA CI_END="2.3541874503299796" CI_START="0.3495759698971974" EFFECT_SIZE="0.9071754853769545" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3718410402418276" LOG_CI_START="-0.45645842872565634" LOG_EFFECT_SIZE="-0.042308694241914344" ORDER="1884" O_E="-0.41152416356877275" SE="0.4865472082199979" STUDY_ID="STD-Shep" TOTAL_1="1331" TOTAL_2="1359" VAR="4.2242540595997005" WEIGHT="8.970197023844863"/>
<DICH_DATA CI_END="7.3988755303994695" CI_START="0.025556895868525387" EFFECT_SIZE="0.4348474347108417" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.8691657213458266" LOG_CI_START="-1.5924918965636188" LOG_EFFECT_SIZE="-0.3616630876088961" ORDER="1885" O_E="-0.3982808022922635" SE="1.4459898701617404" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="0.4782659901155899" WEIGHT="1.015597097289083"/>
<DICH_DATA CI_END="0.6269868527725377" CI_START="0.058289538470302715" EFFECT_SIZE="0.19117210642522842" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.20274156575333868" LOG_CI_START="-1.2344093833594758" LOG_EFFECT_SIZE="-0.7185754745564072" ORDER="1886" O_E="-4.505397448478901" SE="0.6060067828999042" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="2.7229836251554125" WEIGHT="5.782251556304833"/>
<DICH_DATA CI_END="2.0970057040364307" CI_START="0.42043040374249513" EFFECT_SIZE="0.9389595064742419" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3215996117854093" LOG_CI_START="-0.3763058851743656" LOG_EFFECT_SIZE="-0.02735313669447812" ORDER="1887" O_E="-0.37476099426386256" SE="0.4099531436020982" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="5.950199922564199" WEIGHT="12.635240419636405"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.153101523368424" CI_END="0.7193979079456388" CI_START="0.5181792333418888" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.610554712050468" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="366" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.14303082947133863" LOG_CI_START="-0.2855199958769084" LOG_EFFECT_SIZE="-0.2142754126741235" METHOD="PETO" NO="2" P_CHI2="0.7109165536561337" P_Q="1.0" P_Z="3.751506908125164E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8856" TOTAL_2="8472" WEIGHT="100.0" Z="5.894793298437365">
<NAME>Fatal and Non-Fatal Cerebrovascular Accidents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.706768428136317" CI_START="0.0026398965855945864" EFFECT_SIZE="0.1330607946534614" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8265133112431724" LOG_CI_START="-2.5784130857003578" LOG_EFFECT_SIZE="-0.8759498872285929" ORDER="1888" O_E="-0.5042016806722689" SE="2.000070620222123" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.24998234587952825" WEIGHT="0.17512503487454276"/>
<DICH_DATA CI_END="1.3161834192472015" CI_START="0.23515517222616017" EFFECT_SIZE="0.5563338373982765" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.11931641543008924" LOG_CI_START="-0.6286454645276102" LOG_EFFECT_SIZE="-0.2546645245487606" ORDER="1889" O_E="-3.037735849056604" SE="0.4393565107581711" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="5.180430682532589" WEIGHT="3.629148693487663"/>
<DICH_DATA CI_END="1.454734602962048" CI_START="0.35055117115360784" EFFECT_SIZE="0.7141140796721659" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.16278376927908844" LOG_CI_START="-0.4552485776187023" LOG_EFFECT_SIZE="-0.14623240416980698" ORDER="1890" O_E="-2.554828150572831" SE="0.36303525987721935" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="7.587564290582609" WEIGHT="5.31546520345672"/>
<DICH_DATA CI_END="1.3759480369466797" CI_START="0.44517427591970976" EFFECT_SIZE="0.7826472200492915" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.13860203295948959" LOG_CI_START="-0.35146993901139467" LOG_EFFECT_SIZE="-0.10643395302595253" ORDER="1891" O_E="-2.9573378839590454" SE="0.287870702231083" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="12.067159845258018" WEIGHT="8.453644121556959"/>
<DICH_DATA CI_END="0.9131899087060558" CI_START="0.32519057044605476" EFFECT_SIZE="0.5449410494151665" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="37" LOG_CI_END="-0.039438896368716815" LOG_CI_START="-0.4878620561364534" LOG_EFFECT_SIZE="-0.26365047625258503" ORDER="1892" O_E="-8.74969623329283" SE="0.26340598377800867" STUDY_ID="STD-HDFP" TOTAL_1="871" TOTAL_2="775" VAR="14.412812168821125" WEIGHT="10.096889941665816"/>
<DICH_DATA CI_END="0.9331763944632492" CI_START="0.276478885237924" EFFECT_SIZE="0.5079405174541054" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" LOG_CI_END="-0.03003625560912063" LOG_CI_START="-0.5583380302717817" LOG_EFFECT_SIZE="-0.29418714294045123" ORDER="1893" O_E="-7.033962264150944" SE="0.31032707757280814" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="10.383903819531662" WEIGHT="7.274439769461739"/>
<DICH_DATA CI_END="1.0718525210251384" CI_START="0.4976238326182898" EFFECT_SIZE="0.730328254632193" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="63" LOG_CI_END="0.030135033760545753" LOG_CI_START="-0.3030988282232783" LOG_EFFECT_SIZE="-0.1364818972313663" ORDER="1894" O_E="-8.201953125000003" SE="0.19574322006351844" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="26.09916080649265" WEIGHT="18.28375692032269"/>
<DICH_DATA CI_END="0.890676621235228" CI_START="0.4530852792837671" EFFECT_SIZE="0.6352577946659806" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="87" LOG_CI_END="-0.05027994703512504" LOG_CI_START="-0.343820047795841" LOG_EFFECT_SIZE="-0.19704999741548307" ORDER="1895" O_E="-15.260966542750936" SE="0.17242690823377774" STUDY_ID="STD-Shep" TOTAL_1="1331" TOTAL_2="1359" VAR="33.63488274527685" WEIGHT="23.56290398445348"/>
<DICH_DATA CI_END="0.8751838136636512" CI_START="0.04379411678421271" EFFECT_SIZE="0.1957751315750767" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="-0.05790072311937837" LOG_CI_START="-1.3585842278466917" LOG_EFFECT_SIZE="-0.7082424754830351" ORDER="1896" O_E="-2.7936962750716337" SE="0.7640279291640109" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="1.7130953287569972" WEIGHT="1.2001082641914425"/>
<DICH_DATA CI_END="0.7256700984487214" CI_START="0.22245911996704656" EFFECT_SIZE="0.4017859274381105" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="33" LOG_CI_END="-0.13926077184234578" LOG_CI_START="-0.6527497851500361" LOG_EFFECT_SIZE="-0.39600527849619105" ORDER="1897" O_E="-10.022571148184493" SE="0.301625988228547" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="10.991639709118502" WEIGHT="7.700188909801822"/>
<DICH_DATA CI_END="0.9780207855981858" CI_START="0.4108234526757189" EFFECT_SIZE="0.6338721290040017" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="50" LOG_CI_END="-0.009651915176949069" LOG_CI_START="-0.38634477180085713" LOG_EFFECT_SIZE="-0.19799834348890308" ORDER="1898" O_E="-9.311663479923517" SE="0.22127124864059675" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="20.424433838243008" WEIGHT="14.308329156727122"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.740773508013102" CI_END="1.0206215192544674" CI_START="0.664284684173206" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8233973788993572" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="185" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.008864720957749714" LOG_CI_START="-0.177645760588319" LOG_EFFECT_SIZE="-0.08439051981528464" METHOD="PETO" NO="3" P_CHI2="0.6541412106962657" P_Q="1.0" P_Z="0.07612066827115134" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8969" TOTAL_2="8635" WEIGHT="99.99999999999997" Z="1.7736523771047876">
<NAME>Fatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.706768428136317" CI_START="0.0026398965855945864" EFFECT_SIZE="0.1330607946534614" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8265133112431724" LOG_CI_START="-2.5784130857003578" LOG_EFFECT_SIZE="-0.8759498872285929" ORDER="1899" O_E="-0.5042016806722689" SE="2.000070620222123" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.24998234587952825" WEIGHT="0.30004820295235035"/>
<DICH_DATA CI_END="1.40557552048184" CI_START="0.29407112324864654" EFFECT_SIZE="0.6429145916207655" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.14785418487580318" LOG_CI_START="-0.5315476195918416" LOG_EFFECT_SIZE="-0.1918467173580192" ORDER="1900" O_E="-2.7735849056603765" SE="0.3990839830374659" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="6.278724161699097" WEIGHT="7.536211786968416"/>
<DICH_DATA CI_END="2.790533745553505" CI_START="0.48968519521384307" EFFECT_SIZE="1.1689666641706191" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4456872787498526" LOG_CI_START="-0.3100830259269059" LOG_EFFECT_SIZE="0.06780212641147336" ORDER="1901" O_E="0.7921440261865786" SE="0.44394321809047216" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="5.073937908048279" WEIGHT="6.090133868634799"/>
<DICH_DATA CI_END="1.5311155977889062" CI_START="0.3606159782515376" EFFECT_SIZE="0.7430644313334035" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.18500798076138097" LOG_CI_START="-0.44295503437252504" LOG_EFFECT_SIZE="-0.12897352680557198" ORDER="1902" O_E="-2.1825938566552896" SE="0.368868583556714" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="7.34948087145259" WEIGHT="8.821417049885413"/>
<DICH_DATA CI_END="1.563432466933063" CI_START="0.485218157870883" EFFECT_SIZE="0.8709798054839107" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.19407912646686282" LOG_CI_START="-0.3140629553001615" LOG_EFFECT_SIZE="-0.059991914416649354" ORDER="1903" O_E="-1.5504682622268469" SE="0.29848517417382175" STUDY_ID="STD-HDFP" TOTAL_1="984" TOTAL_2="938" VAR="11.224176077707705" WEIGHT="13.47212680114606"/>
<DICH_DATA CI_END="4.6660718390375004" CI_START="0.6940273886141373" EFFECT_SIZE="1.7995504031655134" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.668951420925243" LOG_CI_START="-0.15862339051159877" LOG_EFFECT_SIZE="0.2551640152068221" ORDER="1904" O_E="2.4862533692722373" SE="0.4861215407993859" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="4.231655149387349" WEIGHT="5.079160764815084"/>
<DICH_DATA CI_END="1.5054411102689254" CI_START="0.6112307141312374" EFFECT_SIZE="0.9592558808327413" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.17766377148247461" LOG_CI_START="-0.21379483073706584" LOG_EFFECT_SIZE="-0.018065529627295577" ORDER="1905" O_E="-0.7867187499999986" SE="0.22994472069509073" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="18.912681719476986" WEIGHT="22.70046767892002"/>
<DICH_DATA CI_END="0.9330647831401533" CI_START="0.3407905995265481" EFFECT_SIZE="0.5638968938054558" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.03008820193029066" LOG_CI_START="-0.46751239345361917" LOG_EFFECT_SIZE="-0.24880029769195486" ORDER="1906" O_E="-8.677323420074348" SE="0.2569451353854725" STUDY_ID="STD-Shep" TOTAL_1="1331" TOTAL_2="1359" VAR="15.14674103683759" WEIGHT="18.18029354312064"/>
<DICH_DATA CI_END="5.38376715208013" CI_START="0.33968460697403213" EFFECT_SIZE="1.352324971703933" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="0.7310862683865167" LOG_CI_START="-0.46892413301724106" LOG_EFFECT_SIZE="0.13108106768463781" ORDER="1907" O_E="0.607449856733524" SE="0.7048920499318557" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="2.01258751909913" WEIGHT="2.415663659229129"/>
<DICH_DATA CI_END="2.1447026029275817" CI_START="0.2603319228577494" EFFECT_SIZE="0.7472178749054105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3313670788694755" LOG_CI_START="-0.584472573838863" LOG_EFFECT_SIZE="-0.1265527474846937" ORDER="1908" O_E="-1.006869479882237" SE="0.5379687454802738" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="3.455301191011603" WEIGHT="4.147320521273059"/>
<DICH_DATA CI_END="1.4383227414030793" CI_START="0.39991371594424385" EFFECT_SIZE="0.758422700241506" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.1578563471620646" LOG_CI_START="-0.3980337005007675" LOG_EFFECT_SIZE="-0.12008867666935139" ORDER="1909" O_E="-2.5933715742511154" SE="0.32653256569726236" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="9.378794033371637" WEIGHT="11.257156123055005"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.259763904655498" CI_END="1.001399471250338" CI_START="0.723823580133117" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8513733319900443" ESTIMABLE="YES" EVENTS_1="296" EVENTS_2="324" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="6.073577508061283E-4" LOG_CI_START="-0.14036727290661677" LOG_EFFECT_SIZE="-0.06987995757790529" METHOD="PETO" NO="4" P_CHI2="0.6034799362580603" P_Q="1.0" P_Z="0.052006994542296923" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8868" TOTAL_2="8476" WEIGHT="100.0" Z="1.9430758492527338">
<NAME>Fatal and Nonfatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.706768428136317" CI_START="0.0026398965855945864" EFFECT_SIZE="0.1330607946534614" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8265133112431724" LOG_CI_START="-2.5784130857003578" LOG_EFFECT_SIZE="-0.8759498872285929" ORDER="1910" O_E="-0.5042016806722689" SE="2.000070620222123" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.24998234587952825" WEIGHT="0.17142196700211562"/>
<DICH_DATA CI_END="1.348422008395464" CI_START="0.33650817693061896" EFFECT_SIZE="0.6736134141911674" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.12982583228463823" LOG_CI_START="-0.4730043782373283" LOG_EFFECT_SIZE="-0.17158927297634508" ORDER="1911" O_E="-3.150943396226417" SE="0.3541054497182715" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="7.975075050054409" WEIGHT="5.468798395582135"/>
<DICH_DATA CI_END="2.5163089896994597" CI_START="0.6430949161842209" EFFECT_SIZE="1.2720949331022333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.4007639691587759" LOG_CI_START="-0.19172492360315463" LOG_EFFECT_SIZE="0.10451952277781058" ORDER="1912" O_E="1.986906710310965" SE="0.34803090847567786" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="8.25589896902771" WEIGHT="5.661369548566055"/>
<DICH_DATA CI_END="1.9167310171892746" CI_START="0.6201392202307057" EFFECT_SIZE="1.0902477142336802" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="26" LOG_CI_END="0.2825611708087871" LOG_CI_START="-0.2075108011620971" LOG_EFFECT_SIZE="0.03752518482334505" ORDER="1913" O_E="1.0426621160409546" SE="0.287870702231083" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="12.067159845258018" WEIGHT="8.274889450793317"/>
<DICH_DATA CI_END="1.2493534779797317" CI_START="0.5680758274099954" EFFECT_SIZE="0.8424532691674308" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" LOG_CI_END="0.0966853301414128" LOG_CI_START="-0.2455936902964141" LOG_EFFECT_SIZE="-0.07445418007750064" ORDER="1914" O_E="-4.241007194244602" SE="0.20105639091365612" STUDY_ID="STD-HDFP" TOTAL_1="885" TOTAL_2="783" VAR="24.737980060423922" WEIGHT="16.963730725451445"/>
<DICH_DATA CI_END="1.7614491512505297" CI_START="0.5640068410676604" EFFECT_SIZE="0.996729337131261" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.24587011067363393" LOG_CI_START="-0.24871562825084792" LOG_EFFECT_SIZE="-0.0014227587886069695" ORDER="1915" O_E="-0.03881401617250546" SE="0.29052211128313304" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="11.847906461169948" WEIGHT="8.124539448116087"/>
<DICH_DATA CI_END="1.4635566428947353" CI_START="0.6991109801783597" EFFECT_SIZE="1.011527814328745" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="59" LOG_CI_END="0.1654095352567154" LOG_CI_START="-0.15545387682475567" LOG_EFFECT_SIZE="0.0049778292159798525" ORDER="1916" O_E="0.3226562500000014" SE="0.18847675655616164" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="28.150389024347657" WEIGHT="19.303743396159653"/>
<DICH_DATA CI_END="0.898366550406662" CI_START="0.4201771777359909" EFFECT_SIZE="0.6143884127506711" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="69" LOG_CI_END="-0.046546426875998" LOG_CI_START="-0.37656754034628864" LOG_EFFECT_SIZE="-0.21155698361114333" ORDER="1917" O_E="-12.9623695976155" SE="0.19385603568330728" STUDY_ID="STD-Shep" TOTAL_1="1329" TOTAL_2="1355" VAR="26.609783768624144" WEIGHT="18.247294460212814"/>
<DICH_DATA CI_END="4.0765822419815185" CI_START="0.38265714184589383" EFFECT_SIZE="1.2489729017141942" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.6102962083130525" LOG_CI_START="-0.4171901766627199" LOG_EFFECT_SIZE="0.09655301582516639" ORDER="1918" O_E="0.6103151862464191" SE="0.6035505886744026" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="2.7451914923975766" WEIGHT="1.8824774356307996"/>
<DICH_DATA CI_END="1.3666264591741426" CI_START="0.31986871910874926" EFFECT_SIZE="0.6611664351705692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.13564982481787438" LOG_CI_START="-0.4950282287583489" LOG_EFFECT_SIZE="-0.17968920197023724" ORDER="1919" O_E="-3.014720314033367" SE="0.37046341057738824" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="7.28633875887095" WEIGHT="4.996506924898409"/>
<DICH_DATA CI_END="1.3105633386360669" CI_START="0.4904113811737988" EFFECT_SIZE="0.8016951895928144" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.11745801494718401" LOG_CI_START="-0.30943945952629837" LOG_EFFECT_SIZE="-0.09599072228955716" ORDER="1920" O_E="-3.514977692797963" SE="0.2507616896823031" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="15.902947488928842" WEIGHT="10.905228247587168"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.42765097639774" CI_END="0.944200956350907" CI_START="0.694794798368911" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8099542660468931" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="386" I2="19.534270643810878" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.024935564021570395" LOG_CI_START="-0.15814344158955476" LOG_EFFECT_SIZE="-0.09153950280556258" METHOD="PETO" NO="5" P_CHI2="0.2574543200041124" P_Q="1.0" P_Z="0.007065387377100325" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8969" TOTAL_2="8635" WEIGHT="100.0" Z="2.6937465251638684">
<NAME>Fatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1252539681086904" CI_START="0.008274372913994396" EFFECT_SIZE="0.13260898864359705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.327410835731117" LOG_CI_START="-2.0822649099765944" LOG_EFFECT_SIZE="-0.8774270371227388" ORDER="1921" O_E="-1.0084033613445378" SE="1.4154554611160248" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.49912300035878876" WEIGHT="0.305592438946946"/>
<DICH_DATA CI_END="0.9732755383204871" CI_START="0.37485204039160713" EFFECT_SIZE="0.6040151665336512" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="47" LOG_CI_END="-0.011764191764796738" LOG_CI_START="-0.42614012086320896" LOG_EFFECT_SIZE="-0.2189521563140029" ORDER="1922" O_E="-8.509433962264154" SE="0.2434064719463376" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="16.878574187830907" WEIGHT="10.334055229469433"/>
<DICH_DATA CI_END="1.9215160557125353" CI_START="0.525293289378329" EFFECT_SIZE="1.00466884568922" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.2836440176727199" LOG_CI_START="-0.2795981472733762" LOG_EFFECT_SIZE="0.0020229351996718463" ORDER="1923" O_E="0.0425531914893611" SE="0.33085123578301906" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="9.135545347275306" WEIGHT="5.5933178430516435"/>
<DICH_DATA CI_END="1.1926378903601442" CI_START="0.5250836124358671" EFFECT_SIZE="0.7913498668719141" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" LOG_CI_END="0.07650860285721885" LOG_CI_START="-0.27977153558788653" LOG_EFFECT_SIZE="-0.10163146636533381" ORDER="1924" O_E="-5.343003412969281" SE="0.20928071693778338" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="22.831874635179858" WEIGHT="13.979015694488155"/>
<DICH_DATA CI_END="1.0351660148028656" CI_START="0.46093114368227034" EFFECT_SIZE="0.6907533967372892" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="57" LOG_CI_END="0.015010005378467195" LOG_CI_START="-0.336363946958129" LOG_EFFECT_SIZE="-0.1606769707898309" ORDER="1925" O_E="-8.684703433922998" SE="0.20639879893163224" STUDY_ID="STD-HDFP" TOTAL_1="984" TOTAL_2="938" VAR="23.473922614912087" WEIGHT="14.372115206845413"/>
<DICH_DATA CI_END="2.675140249325219" CI_START="0.6357281976857361" EFFECT_SIZE="1.3040943559651241" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.427346555669904" LOG_CI_START="-0.19672852503686072" LOG_EFFECT_SIZE="0.11530901531652162" ORDER="1926" O_E="1.9757412398921836" SE="0.36658479162862545" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="7.441339393962557" WEIGHT="4.556025374102888"/>
<DICH_DATA CI_END="1.5898795414062024" CI_START="0.7987580818934574" EFFECT_SIZE="1.1269113243442308" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="65" LOG_CI_END="0.20136422087116795" LOG_CI_START="-0.09758473458756532" LOG_EFFECT_SIZE="0.05188974314180136" ORDER="1927" O_E="3.8746093750000057" SE="0.1756040962576557" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="32.4287878337471" WEIGHT="19.854810055004762"/>
<DICH_DATA CI_END="1.0359701786231954" CI_START="0.47471797955194195" EFFECT_SIZE="0.701280022581613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="62" LOG_CI_END="0.015347254013659873" LOG_CI_START="-0.32356431942483593" LOG_EFFECT_SIZE="-0.15410853270558802" ORDER="1928" O_E="-8.95353159851301" SE="0.19907833587711757" STUDY_ID="STD-Shep" TOTAL_1="1331" TOTAL_2="1359" VAR="25.232018620339538" WEIGHT="15.44852492111475"/>
<DICH_DATA CI_END="3.8042744538352227" CI_START="0.3116991360438884" EFFECT_SIZE="1.0889394200479081" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.5802718409379684" LOG_CI_START="-0.506264401482839" LOG_EFFECT_SIZE="0.037003719727564735" ORDER="1929" O_E="0.20916905444126144" SE="0.6382367672391246" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="2.454914446373664" WEIGHT="1.5030429223540984"/>
<DICH_DATA CI_END="0.9569913194592974" CI_START="0.21866153566329635" EFFECT_SIZE="0.4574463810430838" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.01909200154188665" LOG_CI_START="-0.6602276061637965" LOG_EFFECT_SIZE="-0.3396598038528415" ORDER="1930" O_E="-5.51422963689892" SE="0.376606227827337" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="7.050582600848836" WEIGHT="4.31678109692698"/>
<DICH_DATA CI_END="1.3956196347673908" CI_START="0.5222393550180094" EFFECT_SIZE="0.853725657287745" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="34" LOG_CI_END="0.1447670708442493" LOG_CI_START="-0.28213040362923314" LOG_EFFECT_SIZE="-0.06868166639249189" ORDER="1931" O_E="-2.514977692797963" SE="0.2507616896823031" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="15.902947488928842" WEIGHT="9.736719217694935"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.38445303096046" CI_END="0.8014945250613725" CI_START="0.6386786367559807" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7154700766863556" ESTIMABLE="YES" EVENTS_1="594" EVENTS_2="761" I2="12.160909506986291" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.09609943992712358" LOG_CI_START="-0.1947176103711537" LOG_EFFECT_SIZE="-0.14540852514913863" METHOD="PETO" NO="6" P_CHI2="0.32836029029269087" P_Q="1.0" P_Z="7.480010431422116E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8890" TOTAL_2="8512" WEIGHT="99.99999999999999" Z="5.779776101183">
<NAME>Fatal and Nonfatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1252539681086904" CI_START="0.008274372913994396" EFFECT_SIZE="0.13260898864359705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.327410835731117" LOG_CI_START="-2.0822649099765944" LOG_EFFECT_SIZE="-0.8774270371227388" ORDER="1932" O_E="-1.0084033613445378" SE="1.4154554611160248" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.49912300035878876" WEIGHT="0.16749300327647268"/>
<DICH_DATA CI_END="0.8915540363870402" CI_START="0.3625505533645687" EFFECT_SIZE="0.5685361987125677" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="56" LOG_CI_END="-0.049852329444858054" LOG_CI_START="-0.4406314276681116" LOG_EFFECT_SIZE="-0.24524187855648485" ORDER="1933" O_E="-10.716981132075475" SE="0.22954557668407272" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="18.97851131999727" WEIGHT="6.368706423903239"/>
<DICH_DATA CI_END="1.4864956009240868" CI_START="0.5593302475317594" EFFECT_SIZE="0.9118343887021046" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="39" LOG_CI_END="0.17216362830905513" LOG_CI_START="-0.25233169420485796" LOG_EFFECT_SIZE="-0.04008403294790146" ORDER="1934" O_E="-1.4844517184942703" SE="0.24935065373040813" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="16.083441275277494" WEIGHT="5.397194439608186"/>
<DICH_DATA CI_END="1.2556226585522197" CI_START="0.59101731115257" EFFECT_SIZE="0.8614492019148745" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.09885914423364937" LOG_CI_START="-0.22839979825930187" LOG_EFFECT_SIZE="-0.06477032701282626" ORDER="1935" O_E="-4.035836177474408" SE="0.19223352277825123" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="27.06086973122058" WEIGHT="9.080940648492236"/>
<DICH_DATA CI_END="0.9468959533477339" CI_START="0.5148273624267118" EFFECT_SIZE="0.6982033701970656" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="103" LOG_CI_END="-0.02369773944388336" LOG_CI_START="-0.28833837894881986" LOG_EFFECT_SIZE="-0.1560180591963516" ORDER="1936" O_E="-14.866279069767444" SE="0.15545122163749256" STUDY_ID="STD-HDFP" TOTAL_1="905" TOTAL_2="815" VAR="41.38202333557029" WEIGHT="13.886756100498939"/>
<DICH_DATA CI_END="1.0553764483176007" CI_START="0.4613121501710971" EFFECT_SIZE="0.6977520896517102" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="54" LOG_CI_END="0.023407398274085434" LOG_CI_START="-0.33600510666905664" LOG_EFFECT_SIZE="-0.15629885419748557" ORDER="1937" O_E="-8.074393530997305" SE="0.2111206845241944" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="22.43563827279711" WEIGHT="7.5288304326470685"/>
<DICH_DATA CI_END="1.1928671420916643" CI_START="0.7031485003415021" EFFECT_SIZE="0.9158399107204311" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="127" LOG_CI_END="0.07659207596745592" LOG_CI_START="-0.152952945153491" LOG_EFFECT_SIZE="-0.038180434593017544" ORDER="1938" O_E="-4.835546875000006" SE="0.13483588167262422" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="55.00333736853471" WEIGHT="18.457723165357024"/>
<DICH_DATA CI_END="0.8045036912397263" CI_START="0.48152972953318623" EFFECT_SIZE="0.6224085835294332" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="158" LOG_CI_END="-0.09447195892186046" LOG_CI_START="-0.317376894471676" LOG_EFFECT_SIZE="-0.20592442669676822" ORDER="1939" O_E="-27.657249070631977" SE="0.13093546253918795" STUDY_ID="STD-Shep" TOTAL_1="1331" TOTAL_2="1359" VAR="58.3291202926914" WEIGHT="19.573771453679115"/>
<DICH_DATA CI_END="1.5483856961985158" CI_START="0.23258949972114681" EFFECT_SIZE="0.6001152009857711" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="8" LOG_CI_END="0.18987915070507566" LOG_CI_START="-0.6334098954377445" LOG_EFFECT_SIZE="-0.22176537236633442" ORDER="1940" O_E="-2.1833810888252145" SE="0.48360406105079734" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="4.275826963653829" WEIGHT="1.434858940818375"/>
<DICH_DATA CI_END="0.7870423643666449" CI_START="0.31091055311839855" EFFECT_SIZE="0.4946713826701983" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="51" LOG_CI_END="-0.10400189011173527" LOG_CI_START="-0.5073645366145623" LOG_EFFECT_SIZE="-0.3056832133631488" ORDER="1941" O_E="-12.53778213935231" SE="0.2369372152330628" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="17.81285121455832" WEIGHT="5.977540495426304"/>
<DICH_DATA CI_END="0.9837622151314763" CI_START="0.5124943655438856" EFFECT_SIZE="0.7100511194905994" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="86" LOG_CI_END="-0.00710986207251253" LOG_CI_START="-0.2903109049583552" LOG_EFFECT_SIZE="-0.14871038351543386" ORDER="1942" O_E="-12.373486297004462" SE="0.16635369445891532" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="36.13558578535188" WEIGHT="12.126184896293024"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.857480581490655" CI_END="0.9992380304287863" CI_START="0.7939105266461343" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8906770407855833" ESTIMABLE="YES" EVENTS_1="654" EVENTS_2="694" I2="15.66505269584969" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-3.310453194094369E-4" LOG_CI_START="-0.10022843960490155" LOG_EFFECT_SIZE="-0.05027974246215552" METHOD="PETO" NO="7" P_CHI2="0.2947081471978976" P_Q="1.0" P_Z="0.04850079760846441" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8969" TOTAL_2="8635" WEIGHT="100.0" Z="1.9729540511565826">
<NAME>All Cause Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1252539681086904" CI_START="0.008274372913994396" EFFECT_SIZE="0.13260898864359705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.327410835731117" LOG_CI_START="-2.0822649099765944" LOG_EFFECT_SIZE="-0.8774270371227388" ORDER="1943" O_E="-1.0084033613445378" SE="1.4154554611160248" STUDY_ID="STD-Australian" TOTAL_1="300" TOTAL_2="295" VAR="0.49912300035878876" WEIGHT="0.17186645055805164"/>
<DICH_DATA CI_END="0.9506441155355394" CI_START="0.40625810073544544" EFFECT_SIZE="0.6214554471985869" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="64" LOG_CI_END="-0.021982035729146605" LOG_CI_START="-0.39119796614937" LOG_EFFECT_SIZE="-0.20659000093925828" ORDER="1944" O_E="-10.113207547169807" SE="0.21687926517717074" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="21.2600329740525" WEIGHT="7.320613162228524"/>
<DICH_DATA CI_END="2.100235198070248" CI_START="0.7237607765404842" EFFECT_SIZE="1.2329103202881304" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.32226793259315945" LOG_CI_START="-0.1404049567260301" LOG_EFFECT_SIZE="0.09093148793356469" ORDER="1945" O_E="2.8346972176759415" SE="0.27177634545383106" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="13.538691464090082" WEIGHT="4.661870611975659"/>
<DICH_DATA CI_END="1.2469528831854277" CI_START="0.6279558045392946" EFFECT_SIZE="0.884890558760403" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="104" LOG_CI_END="0.09585004372780996" LOG_CI_START="-0.20207092078529437" LOG_EFFECT_SIZE="-0.05311043852874221" ORDER="1946" O_E="-3.99317406143345" SE="0.175000249287556" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="32.652968196096246" WEIGHT="11.243620790895076"/>
<DICH_DATA CI_END="1.1283332359685208" CI_START="0.5980088137946435" EFFECT_SIZE="0.8214336370070359" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" LOG_CI_END="0.05243738082587056" LOG_CI_START="-0.2232924150848832" LOG_EFFECT_SIZE="-0.0854275171295063" ORDER="1947" O_E="-7.498439125910508" SE="0.16196504700247907" STUDY_ID="STD-HDFP" TOTAL_1="984" TOTAL_2="938" VAR="38.12039544978867" WEIGHT="13.126257566000618"/>
<DICH_DATA CI_END="1.8511211294447207" CI_START="0.8229910290586929" EFFECT_SIZE="1.2342836315993178" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="43" LOG_CI_END="0.267434838055038" LOG_CI_START="-0.08460489875072072" LOG_EFFECT_SIZE="0.0914149696521586" ORDER="1948" O_E="4.922371967654989" SE="0.20678988402450457" STUDY_ID="STD-MRC" TOTAL_1="1858" TOTAL_2="1852" VAR="23.38521788676581" WEIGHT="8.052392678429952"/>
<DICH_DATA CI_END="1.1304547991020852" CI_START="0.6726719840782458" EFFECT_SIZE="0.872023665173586" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="135" LOG_CI_END="0.05325320189323516" LOG_CI_START="-0.1721966597463535" LOG_EFFECT_SIZE="-0.059471728926559185" ORDER="1949" O_E="-7.808203125000006" SE="0.132430364721908" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="57.01968972442019" WEIGHT="19.633981358929674"/>
<DICH_DATA CI_END="1.0832709882999574" CI_START="0.6226053908013023" EFFECT_SIZE="0.8212492660661609" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="120" LOG_CI_END="0.03473711221326975" LOG_CI_START="-0.2057871233176169" LOG_EFFECT_SIZE="-0.08552500555217356" ORDER="1950" O_E="-9.865427509293681" SE="0.14128512656501066" STUDY_ID="STD-Shep" TOTAL_1="1331" TOTAL_2="1359" VAR="50.09646829299621" WEIGHT="17.25006097659716"/>
<DICH_DATA CI_END="3.790974902758286" CI_START="0.5347715366013901" EFFECT_SIZE="1.4238347776218117" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="0.5787509092933123" LOG_CI_START="-0.2718317162677928" LOG_EFFECT_SIZE="0.15345959651275975" ORDER="1951" O_E="1.415472779369626" SE="0.49963644470649504" STUDY_ID="STD-Shep-Pilot" TOTAL_1="279" TOTAL_2="70" VAR="4.0058232351299985" WEIGHT="1.3793526254848365"/>
<DICH_DATA CI_END="1.208840421381183" CI_START="0.39214104937542293" EFFECT_SIZE="0.688502687988831" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.08236897357558817" LOG_CI_START="-0.40655769331798813" LOG_EFFECT_SIZE="-0.1620943598712" ORDER="1952" O_E="-4.5250245338567225" SE="0.2871979443593208" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="12.123760426287193" WEIGHT="4.174657690357548"/>
<DICH_DATA CI_END="1.4515830776683027" CI_START="0.7666901301512484" EFFECT_SIZE="1.054947590519482" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="75" LOG_CI_END="0.16184189661992476" LOG_CI_START="-0.11538012752039283" LOG_EFFECT_SIZE="0.023230884549765962" ORDER="1953" O_E="2.01720841300191" SE="0.16284158925117379" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="37.71111172021089" WEIGHT="12.985326088542898"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>White Women: Hypertension Treatment versus Placebo or Usual Care</NAME>
<DICH_OUTCOME CHI2="8.624050878945571" CI_END="1.0011951258266418" CI_START="0.5626431726315901" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7505435377234193" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="107" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="5.187266415931255E-4" LOG_CI_START="-0.249766946688586" LOG_EFFECT_SIZE="-0.12462411002349648" METHOD="PETO" NO="1" P_CHI2="0.5681149274276132" P_Q="1.0" P_Z="0.05095722930470472" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11656" TOTAL_2="11281" WEIGHT="100.0" Z="1.9518397837273074">
<NAME>Fatal Cerebrovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.491997718412203" CI_START="0.049195111746119784" EFFECT_SIZE="0.3501344116598136" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.39654764036215456" LOG_CI_START="-1.3080780485975885" LOG_EFFECT_SIZE="-0.45576520411771704" ORDER="1954" O_E="-1.0467032967032965" SE="1.0013055677282003" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="0.9973939691779841" WEIGHT="2.1558270824872054"/>
<DICH_DATA CI_END="2.009494487409968" CI_START="0.25412361628333985" EFFECT_SIZE="0.7146047901057321" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3030868191417806" LOG_CI_START="-0.594954973104111" LOG_EFFECT_SIZE="-0.14593407698116517" ORDER="1955" O_E="-1.2075471698113205" SE="0.5275141941438024" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="3.5936162638328164" WEIGHT="7.767457499289118"/>
<DICH_DATA CI_END="2.0060862672089743" CI_START="0.1443628814654563" EFFECT_SIZE="0.5381490444129479" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3023496049392639" LOG_CI_START="-0.8405444580612804" LOG_EFFECT_SIZE="-0.2690974265610082" ORDER="1956" O_E="-1.3747954173486088" SE="0.6713416300233732" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="2.218772847926197" WEIGHT="4.795788568271347"/>
<DICH_DATA CI_END="1.609711591963711" CI_START="0.43246818797849096" EFFECT_SIZE="0.8343554730116642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.20674807153572994" LOG_CI_START="-0.364045833386511" LOG_EFFECT_SIZE="-0.07864888092539057" ORDER="1957" O_E="-1.6109215017064855" SE="0.33528716522672236" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="8.895413523227475" WEIGHT="19.227079745731455"/>
<DICH_DATA CI_END="1.8224832640674347" CI_START="0.2059773736519551" EFFECT_SIZE="0.6126910447013671" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2606635488657131" LOG_CI_START="-0.6861804836978166" LOG_EFFECT_SIZE="-0.21275846741605178" ORDER="1958" O_E="-1.5836909871244638" SE="0.5561808716813688" STUDY_ID="STD-HDFP" TOTAL_1="1180" TOTAL_2="1150" VAR="3.2327186085764104" WEIGHT="6.98739168452475"/>
<DICH_DATA CI_END="1.8285191546130017" CI_START="0.3920481643439139" EFFECT_SIZE="0.8466803281249142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.26209951414037874" LOG_CI_START="-0.4066605752656577" LOG_EFFECT_SIZE="-0.07228053056263949" ORDER="1959" O_E="-1.0785024154589369" SE="0.39283298693293806" STUDY_ID="STD-MRC" TOTAL_1="4165" TOTAL_2="4115" VAR="6.480135717144916" WEIGHT="14.00655358757309"/>
<DICH_DATA CI_END="2.087660285089157" CI_START="0.5498852463980316" EFFECT_SIZE="1.0714352944819558" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.3196598294286511" LOG_CI_START="-0.2597279324255563" LOG_EFFECT_SIZE="0.029965948501547317" ORDER="1960" O_E="0.595703125" SE="0.34033523932883736" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="8.633485438535809" WEIGHT="18.660932690413205"/>
<DICH_DATA CI_END="2.5712124529848306" CI_START="0.29058677356593476" EFFECT_SIZE="0.8643843652365623" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.41013796281437603" LOG_CI_START="-0.5367241570650256" LOG_EFFECT_SIZE="-0.06329309712532476" ORDER="1961" O_E="-0.47111111111111104" SE="0.5561914962602456" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="3.2325951045457786" WEIGHT="6.987124735513366"/>
<DICH_DATA CI_END="4.589050228047745" CI_START="0.0039153193134282074" EFFECT_SIZE="0.13404326535923936" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6617228111582885" LOG_CI_START="-2.407232813323826" LOG_EFFECT_SIZE="-0.8727550010827687" ORDER="1962" O_E="-0.6183745583038869" SE="1.8027197253961418" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="0.30771139447789864" WEIGHT="0.6651058441350767"/>
<DICH_DATA CI_END="0.6269868527725377" CI_START="0.058289538470302715" EFFECT_SIZE="0.19117210642522842" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.20274156575333868" LOG_CI_START="-1.2344093833594758" LOG_EFFECT_SIZE="-0.7185754745564072" ORDER="1963" O_E="-4.505397448478901" SE="0.6060067828999042" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="2.7229836251554125" WEIGHT="5.885619951278931"/>
<DICH_DATA CI_END="2.0970057040364307" CI_START="0.42043040374249513" EFFECT_SIZE="0.9389595064742419" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3215996117854093" LOG_CI_START="-0.3763058851743656" LOG_EFFECT_SIZE="-0.02735313669447812" ORDER="1964" O_E="-0.37476099426386256" SE="0.4099531436020982" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="5.950199922564199" WEIGHT="12.861118610782475"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.357795766307883" CI_END="0.7548371194140002" CI_START="0.5412198440648363" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6391657281672691" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="349" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.12214675137900213" LOG_CI_START="-0.26662628818331985" LOG_EFFECT_SIZE="-0.19438651978116098" METHOD="PETO" NO="2" P_CHI2="0.7843606903455094" P_Q="1.0" P_Z="1.3350165976887699E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11550" TOTAL_2="11123" WEIGHT="99.99999999999999" Z="5.27397285841482">
<NAME>Fatal and Non-Fatal Cerebrovascular Accidents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.491997718412203" CI_START="0.049195111746119784" EFFECT_SIZE="0.3501344116598136" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.39654764036215456" LOG_CI_START="-1.3080780485975885" LOG_EFFECT_SIZE="-0.45576520411771704" ORDER="1965" O_E="-1.0467032967032965" SE="1.0013055677282003" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="0.9973939691779841" WEIGHT="0.7183806456389905"/>
<DICH_DATA CI_END="1.3161834192472015" CI_START="0.23515517222616017" EFFECT_SIZE="0.5563338373982765" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.11931641543008924" LOG_CI_START="-0.6286454645276102" LOG_EFFECT_SIZE="-0.2546645245487606" ORDER="1966" O_E="-3.037735849056604" SE="0.4393565107581711" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="5.180430682532589" WEIGHT="3.731244877561211"/>
<DICH_DATA CI_END="1.454734602962048" CI_START="0.35055117115360784" EFFECT_SIZE="0.7141140796721659" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.16278376927908844" LOG_CI_START="-0.4552485776187023" LOG_EFFECT_SIZE="-0.14623240416980698" ORDER="1967" O_E="-2.554828150572831" SE="0.36303525987721935" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="7.587564290582609" WEIGHT="5.465001295715074"/>
<DICH_DATA CI_END="1.3759480369466797" CI_START="0.44517427591970976" EFFECT_SIZE="0.7826472200492915" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.13860203295948959" LOG_CI_START="-0.35146993901139467" LOG_EFFECT_SIZE="-0.10643395302595253" ORDER="1968" O_E="-2.9573378839590454" SE="0.287870702231083" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="12.067159845258018" WEIGHT="8.691464304531415"/>
<DICH_DATA CI_END="1.2642058227579909" CI_START="0.3824582817961692" EFFECT_SIZE="0.6953459475748267" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.10181778629694968" LOG_CI_START="-0.4174159303765844" LOG_EFFECT_SIZE="-0.15779907203981733" ORDER="1969" O_E="-3.905882352941177" SE="0.30500045542238385" STUDY_ID="STD-HDFP" TOTAL_1="1062" TOTAL_2="978" VAR="10.749766338407968" WEIGHT="7.742601540912007"/>
<DICH_DATA CI_END="0.8498108209639977" CI_START="0.3248547740653758" EFFECT_SIZE="0.5254189778096819" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="44" LOG_CI_END="-0.0706777431746842" LOG_CI_START="-0.4883107464605214" LOG_EFFECT_SIZE="-0.2794942448176027" ORDER="1970" O_E="-10.693594991572354" SE="0.2453196934468083" STUDY_ID="STD-MRC" TOTAL_1="4177" TOTAL_2="4129" VAR="16.61633247431945" WEIGHT="11.9680407340859"/>
<DICH_DATA CI_END="1.0718525210251384" CI_START="0.4976238326182898" EFFECT_SIZE="0.730328254632193" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="63" LOG_CI_END="0.030135033760545753" LOG_CI_START="-0.3030988282232783" LOG_EFFECT_SIZE="-0.1364818972313663" ORDER="1971" O_E="-8.201953125000003" SE="0.19574322006351844" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="26.09916080649265" WEIGHT="18.79812047215042"/>
<DICH_DATA CI_END="1.0550433439013753" CI_START="0.49665111704438236" EFFECT_SIZE="0.723870468577672" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="66" LOG_CI_END="0.02327030193751866" LOG_CI_START="-0.3039485833963866" LOG_EFFECT_SIZE="-0.140339140729434" ORDER="1972" O_E="-8.74666666666667" SE="0.1922099930047415" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="27.067495558519838" WEIGHT="19.495570994063318"/>
<DICH_DATA CI_END="1.394183885578629" CI_START="0.030839124446486982" EFFECT_SIZE="0.2073533466058508" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.1443200587155613" LOG_CI_START="-1.5108979604997148" LOG_EFFECT_SIZE="-0.6832889508920768" ORDER="1973" O_E="-1.6643109540636045" SE="0.9722832579483907" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="1.0578263596642352" WEIGHT="0.7619075377564558"/>
<DICH_DATA CI_END="0.7256700984487214" CI_START="0.22245911996704656" EFFECT_SIZE="0.4017859274381105" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="33" LOG_CI_END="-0.13926077184234578" LOG_CI_START="-0.6527497851500361" LOG_EFFECT_SIZE="-0.39600527849619105" ORDER="1974" O_E="-10.022571148184493" SE="0.301625988228547" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="10.991639709118502" WEIGHT="7.916812688746716"/>
<DICH_DATA CI_END="0.9780207855981858" CI_START="0.4108234526757189" EFFECT_SIZE="0.6338721290040017" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="50" LOG_CI_END="-0.009651915176949069" LOG_CI_START="-0.38634477180085713" LOG_EFFECT_SIZE="-0.19799834348890308" ORDER="1975" O_E="-9.311663479923517" SE="0.22127124864059675" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="20.424433838243008" WEIGHT="14.710854908838494"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.023112417390665" CI_END="1.11253806202215" CI_START="0.7188485274574161" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8942853837701643" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="172" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.04631487793919237" LOG_CI_START="-0.1433626125652947" LOG_EFFECT_SIZE="-0.04852386731305118" METHOD="PETO" NO="3" P_CHI2="0.6265793019465334" P_Q="1.0" P_Z="0.3159536240825739" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11668" TOTAL_2="11295" WEIGHT="100.0" Z="1.0028077878005337">
<NAME>Fatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.508943809736044" CI_START="0.00255726450229788" EFFECT_SIZE="0.1290158554290499" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.813510522390415" LOG_CI_START="-2.592224349819767" LOG_EFFECT_SIZE="-0.8893569137146762" ORDER="1976" O_E="-0.5116758241758241" SE="2.0005455225957713" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="0.24986367512981522" WEIGHT="0.31017723329192465"/>
<DICH_DATA CI_END="1.40557552048184" CI_START="0.29407112324864654" EFFECT_SIZE="0.6429145916207655" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.14785418487580318" LOG_CI_START="-0.5315476195918416" LOG_EFFECT_SIZE="-0.1918467173580192" ORDER="1977" O_E="-2.7735849056603765" SE="0.3990839830374659" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="6.278724161699097" WEIGHT="7.794319394634549"/>
<DICH_DATA CI_END="2.790533745553505" CI_START="0.48968519521384307" EFFECT_SIZE="1.1689666641706191" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4456872787498526" LOG_CI_START="-0.3100830259269059" LOG_EFFECT_SIZE="0.06780212641147336" ORDER="1978" O_E="0.7921440261865786" SE="0.44394321809047216" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="5.073937908048279" WEIGHT="6.29871477474972"/>
<DICH_DATA CI_END="1.5311155977889062" CI_START="0.3606159782515376" EFFECT_SIZE="0.7430644313334035" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.18500798076138097" LOG_CI_START="-0.44295503437252504" LOG_EFFECT_SIZE="-0.12897352680557198" ORDER="1979" O_E="-2.1825938566552896" SE="0.368868583556714" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="7.34948087145259" WEIGHT="9.123541633871803"/>
<DICH_DATA CI_END="2.145062880493027" CI_START="0.6049035908776491" EFFECT_SIZE="1.139103260933172" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.3314400276400314" LOG_CI_START="-0.21831383739094748" LOG_EFFECT_SIZE="0.056563095124541996" ORDER="1980" O_E="1.2489270386266078" SE="0.3229281416447179" STUDY_ID="STD-HDFP" TOTAL_1="1180" TOTAL_2="1150" VAR="9.589328872138829" WEIGHT="11.904057270994139"/>
<DICH_DATA CI_END="3.6830153345216443" CI_START="0.8350190441382712" EFFECT_SIZE="1.7536784038639635" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5662035270776304" LOG_CI_START="-0.07830361952256784" LOG_EFFECT_SIZE="0.2439499537775313" ORDER="1981" O_E="3.919094630387672" SE="0.37858668827478564" STUDY_ID="STD-MRC" TOTAL_1="4177" TOTAL_2="4129" VAR="6.977009610693333" WEIGHT="8.661161077422221"/>
<DICH_DATA CI_END="1.5054411102689254" CI_START="0.6112307141312374" EFFECT_SIZE="0.9592558808327413" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.17766377148247461" LOG_CI_START="-0.21379483073706584" LOG_EFFECT_SIZE="-0.018065529627295577" ORDER="1982" O_E="-0.7867187499999986" SE="0.22994472069509073" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="18.912681719476986" WEIGHT="23.477935665639826"/>
<DICH_DATA CI_END="1.1150853055862044" CI_START="0.35115819274118376" EFFECT_SIZE="0.6257566145570514" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" LOG_CI_END="0.04730809279066001" LOG_CI_START="-0.4544971947664712" LOG_EFFECT_SIZE="-0.20359455098790555" ORDER="1983" O_E="-5.395555555555557" SE="0.2947629098872933" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="11.509443613348045" WEIGHT="14.287660560755592"/>
<DICH_DATA CI_END="5.111806286183181" CI_START="0.2708767579956968" EFFECT_SIZE="1.1767198112989021" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="0.7085743877098626" LOG_CI_START="-0.5672282570829136" LOG_EFFECT_SIZE="0.07067306531347457" ORDER="1984" O_E="0.2897526501766787" SE="0.7494127888762206" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="1.7805648662671287" WEIGHT="2.210368048211107"/>
<DICH_DATA CI_END="2.1447026029275817" CI_START="0.2603319228577494" EFFECT_SIZE="0.7472178749054105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3313670788694755" LOG_CI_START="-0.584472573838863" LOG_EFFECT_SIZE="-0.1265527474846937" ORDER="1985" O_E="-1.006869479882237" SE="0.5379687454802738" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="3.455301191011603" WEIGHT="4.289362041366944"/>
<DICH_DATA CI_END="1.4383227414030793" CI_START="0.39991371594424385" EFFECT_SIZE="0.758422700241506" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.1578563471620646" LOG_CI_START="-0.3980337005007675" LOG_EFFECT_SIZE="-0.12008867666935139" ORDER="1986" O_E="-2.5933715742511154" SE="0.32653256569726236" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="9.378794033371637" WEIGHT="11.64270229906218"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.8316463355123105" CI_END="1.0508641055308177" CI_START="0.7586734792903553" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8928956978306103" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="314" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.021546558051126576" LOG_CI_START="-0.11994509716588468" LOG_EFFECT_SIZE="-0.04919926955737907" METHOD="PETO" NO="4" P_CHI2="0.6452775721456974" P_Q="1.0" P_Z="0.172872561588979" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11570" TOTAL_2="11137" WEIGHT="100.00000000000001" Z="1.363031568897039">
<NAME>Fatal and Nonfatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.508943809736044" CI_START="0.00255726450229788" EFFECT_SIZE="0.1290158554290499" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.813510522390415" LOG_CI_START="-2.592224349819767" LOG_EFFECT_SIZE="-0.8893569137146762" ORDER="1987" O_E="-0.5116758241758241" SE="2.0005455225957713" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="0.24986367512981522" WEIGHT="0.17259967826529204"/>
<DICH_DATA CI_END="1.348422008395464" CI_START="0.33650817693061896" EFFECT_SIZE="0.6736134141911674" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.12982583228463823" LOG_CI_START="-0.4730043782373283" LOG_EFFECT_SIZE="-0.17158927297634508" ORDER="1988" O_E="-3.150943396226417" SE="0.3541054497182715" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="7.975075050054409" WEIGHT="5.5089855981098435"/>
<DICH_DATA CI_END="2.5163089896994597" CI_START="0.6430949161842209" EFFECT_SIZE="1.2720949331022333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.4007639691587759" LOG_CI_START="-0.19172492360315463" LOG_EFFECT_SIZE="0.10451952277781058" ORDER="1989" O_E="1.986906710310965" SE="0.34803090847567786" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="8.25589896902771" WEIGHT="5.702971850968759"/>
<DICH_DATA CI_END="1.9167310171892746" CI_START="0.6201392202307057" EFFECT_SIZE="1.0902477142336802" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="26" LOG_CI_END="0.2825611708087871" LOG_CI_START="-0.2075108011620971" LOG_EFFECT_SIZE="0.03752518482334505" ORDER="1990" O_E="1.0426621160409546" SE="0.287870702231083" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="12.067159845258018" WEIGHT="8.335697078758187"/>
<DICH_DATA CI_END="1.2863193991716262" CI_START="0.56887308380333" EFFECT_SIZE="0.8554253230778298" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" LOG_CI_END="0.10934881934617621" LOG_CI_START="-0.244984614364112" LOG_EFFECT_SIZE="-0.06781789750896794" ORDER="1991" O_E="-3.604628736740601" SE="0.20813721294020796" STUDY_ID="STD-HDFP" TOTAL_1="1082" TOTAL_2="992" VAR="23.08344002362093" WEIGHT="15.945472343121395"/>
<DICH_DATA CI_END="1.758353955480017" CI_START="0.6952052466261572" EFFECT_SIZE="1.1056296374806367" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.24510630272797718" LOG_CI_START="-0.15788695898144028" LOG_EFFECT_SIZE="0.043609671873268405" ORDER="1992" O_E="1.7919576209968682" SE="0.23672023677692977" STUDY_ID="STD-MRC" TOTAL_1="4177" TOTAL_2="4129" VAR="17.845520802472652" WEIGHT="12.32724663712359"/>
<DICH_DATA CI_END="1.4635566428947353" CI_START="0.6991109801783597" EFFECT_SIZE="1.011527814328745" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="59" LOG_CI_END="0.1654095352567154" LOG_CI_START="-0.15545387682475567" LOG_EFFECT_SIZE="0.0049778292159798525" ORDER="1993" O_E="0.3226562500000014" SE="0.18847675655616164" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="28.150389024347657" WEIGHT="19.445596027997585"/>
<DICH_DATA CI_END="1.0144972415868379" CI_START="0.4365458258441659" EFFECT_SIZE="0.6654881938435531" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="54" LOG_CI_END="0.006250870526344824" LOG_CI_START="-0.35997016005320115" LOG_EFFECT_SIZE="-0.17685964476342814" ORDER="1994" O_E="-8.799999999999997" SE="0.2151200461857635" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="21.609177412183193" WEIGHT="14.927088009022007"/>
<DICH_DATA CI_END="5.650338701162172" CI_START="0.4354632527551212" EFFECT_SIZE="1.5686028401020529" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="0.7520744817374794" LOG_CI_START="-0.36104848772640963" LOG_EFFECT_SIZE="0.19551299700553487" ORDER="1995" O_E="1.053003533568905" SE="0.6538539423106521" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="2.3390446213693648" WEIGHT="1.615754466457618"/>
<DICH_DATA CI_END="1.3666264591741426" CI_START="0.31986871910874926" EFFECT_SIZE="0.6611664351705692" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.13564982481787438" LOG_CI_START="-0.4950282287583489" LOG_EFFECT_SIZE="-0.17968920197023724" ORDER="1996" O_E="-3.014720314033367" SE="0.37046341057738824" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="7.28633875887095" WEIGHT="5.033223516222053"/>
<DICH_DATA CI_END="1.3105633386360669" CI_START="0.4904113811737988" EFFECT_SIZE="0.8016951895928144" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.11745801494718401" LOG_CI_START="-0.30943945952629837" LOG_EFFECT_SIZE="-0.09599072228955716" ORDER="1997" O_E="-3.514977692797963" SE="0.2507616896823031" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="15.902947488928842" WEIGHT="10.98536479395368"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.435849532270465" CI_END="1.0051945535298035" CI_START="0.7351742510962691" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8596471096312264" ESTIMABLE="YES" EVENTS_1="329" EVENTS_2="361" I2="4.176464320635333" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.002250126778516514" LOG_CI_START="-0.13360971218047907" LOG_EFFECT_SIZE="-0.0656797927009813" METHOD="PETO" NO="5" P_CHI2="0.4031219279715401" P_Q="1.0" P_Z="0.05808688104245245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11668" TOTAL_2="11295" WEIGHT="99.99999999999999" Z="1.8950416722462409">
<NAME>Fatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6571783811696175" CI_START="0.04945160585591492" EFFECT_SIZE="0.2862693349601788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2193692590457697" LOG_CI_START="-1.3058196008708707" LOG_EFFECT_SIZE="-0.5432251709125505" ORDER="1998" O_E="-1.558379120879121" SE="0.8959034861216529" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="1.2458838234136147" WEIGHT="0.7934780949050986"/>
<DICH_DATA CI_END="0.9732755383204871" CI_START="0.37485204039160713" EFFECT_SIZE="0.6040151665336512" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="47" LOG_CI_END="-0.011764191764796738" LOG_CI_START="-0.42614012086320896" LOG_EFFECT_SIZE="-0.2189521563140029" ORDER="1999" O_E="-8.509433962264154" SE="0.2434064719463376" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="16.878574187830907" WEIGHT="10.749620983583664"/>
<DICH_DATA CI_END="1.9215160557125353" CI_START="0.525293289378329" EFFECT_SIZE="1.00466884568922" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.2836440176727199" LOG_CI_START="-0.2795981472733762" LOG_EFFECT_SIZE="0.0020229351996718463" ORDER="2000" O_E="0.0425531914893611" SE="0.33085123578301906" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="9.135545347275306" WEIGHT="5.818243227698314"/>
<DICH_DATA CI_END="1.1926378903601442" CI_START="0.5250836124358671" EFFECT_SIZE="0.7913498668719141" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" LOG_CI_END="0.07650860285721885" LOG_CI_START="-0.27977153558788653" LOG_EFFECT_SIZE="-0.10163146636533381" ORDER="2001" O_E="-5.343003412969281" SE="0.20928071693778338" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="22.831874635179858" WEIGHT="14.541157087180608"/>
<DICH_DATA CI_END="1.6005151040679921" CI_START="0.5925806375688498" EFFECT_SIZE="0.9738758959986559" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="32" LOG_CI_END="0.2042597769384027" LOG_CI_START="-0.22725254309286316" LOG_EFFECT_SIZE="-0.011496383077230237" ORDER="2002" O_E="-0.41201716738197547" SE="0.253472472806799" STUDY_ID="STD-HDFP" TOTAL_1="1180" TOTAL_2="1150" VAR="15.564615500487545" WEIGHT="9.91278739089716"/>
<DICH_DATA CI_END="1.8502481561965207" CI_START="0.6527045533343742" EFFECT_SIZE="1.0989383041590641" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.26722998009987914" LOG_CI_START="-0.1852833576102967" LOG_EFFECT_SIZE="0.04097331124479127" ORDER="2003" O_E="1.3352997832891873" SE="0.26580857454810486" STUDY_ID="STD-MRC" TOTAL_1="4177" TOTAL_2="4129" VAR="14.153440616611718" WEIGHT="9.014038777749802"/>
<DICH_DATA CI_END="1.5898795414062024" CI_START="0.7987580818934574" EFFECT_SIZE="1.1269113243442308" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="65" LOG_CI_END="0.20136422087116795" LOG_CI_START="-0.09758473458756532" LOG_EFFECT_SIZE="0.05188974314180136" ORDER="2004" O_E="3.8746093750000057" SE="0.1756040962576557" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="32.4287878337471" WEIGHT="20.65323612590225"/>
<DICH_DATA CI_END="1.2178677610058695" CI_START="0.5042418321826212" EFFECT_SIZE="0.7836452457367085" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="46" LOG_CI_END="0.08560013412336724" LOG_CI_START="-0.2973611278534143" LOG_EFFECT_SIZE="-0.10588049686502356" ORDER="2005" O_E="-4.817777777777778" SE="0.22495334097398154" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="19.76128150014547" WEIGHT="12.585558703745383"/>
<DICH_DATA CI_END="3.338561523336974" CI_START="0.2177774158391501" EFFECT_SIZE="0.8526800696464898" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.5235593838642632" LOG_CI_START="-0.6619871598648461" LOG_EFFECT_SIZE="-0.06921388800029143" ORDER="2006" O_E="-0.32862190812720904" SE="0.696395908336517" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="2.0619948605049223" WEIGHT="1.3132426337590979"/>
<DICH_DATA CI_END="0.9569913194592974" CI_START="0.21866153566329635" EFFECT_SIZE="0.4574463810430838" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.01909200154188665" LOG_CI_START="-0.6602276061637965" LOG_EFFECT_SIZE="-0.3396598038528415" ORDER="2007" O_E="-5.51422963689892" SE="0.376606227827337" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="7.050582600848836" WEIGHT="4.4903728140270465"/>
<DICH_DATA CI_END="1.3956196347673908" CI_START="0.5222393550180094" EFFECT_SIZE="0.853725657287745" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="34" LOG_CI_END="0.1447670708442493" LOG_CI_START="-0.28213040362923314" LOG_EFFECT_SIZE="-0.06868166639249189" ORDER="2008" O_E="-2.514977692797963" SE="0.2507616896823031" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="15.902947488928842" WEIGHT="10.128264160551572"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.499218867826858" CI_END="0.8394310220712033" CI_START="0.6668988767678488" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.748208263616069" ESTIMABLE="YES" EVENTS_1="583" EVENTS_2="723" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.07601498501088985" LOG_CI_START="-0.1759400140462382" LOG_EFFECT_SIZE="-0.12597749952856396" METHOD="PETO" NO="6" P_CHI2="0.48546938988039057" P_Q="1.0" P_Z="7.735209632292264E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11515" TOTAL_2="11065" WEIGHT="100.00000000000003" Z="4.941932253050484">
<NAME>Fatal and Nonfatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6571783811696175" CI_START="0.04945160585591492" EFFECT_SIZE="0.2862693349601788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2193692590457697" LOG_CI_START="-1.3058196008708707" LOG_EFFECT_SIZE="-0.5432251709125505" ORDER="2009" O_E="-1.558379120879121" SE="0.8959034861216529" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="1.2458838234136147" WEIGHT="0.4292411178990584"/>
<DICH_DATA CI_END="0.8915540363870402" CI_START="0.3625505533645687" EFFECT_SIZE="0.5685361987125677" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="56" LOG_CI_END="-0.049852329444858054" LOG_CI_START="-0.4406314276681116" LOG_EFFECT_SIZE="-0.24524187855648485" ORDER="2010" O_E="-10.716981132075475" SE="0.22954557668407272" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="18.97851131999727" WEIGHT="6.538617214513022"/>
<DICH_DATA CI_END="1.4864956009240868" CI_START="0.5593302475317594" EFFECT_SIZE="0.9118343887021046" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="39" LOG_CI_END="0.17216362830905513" LOG_CI_START="-0.25233169420485796" LOG_EFFECT_SIZE="-0.04008403294790146" ORDER="2011" O_E="-1.4844517184942703" SE="0.24935065373040813" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="16.083441275277494" WEIGHT="5.541186251016964"/>
<DICH_DATA CI_END="1.2556226585522197" CI_START="0.59101731115257" EFFECT_SIZE="0.8614492019148745" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.09885914423364937" LOG_CI_START="-0.22839979825930187" LOG_EFFECT_SIZE="-0.06477032701282626" ORDER="2012" O_E="-4.035836177474408" SE="0.19223352277825123" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="27.06086973122058" WEIGHT="9.323211166611076"/>
<DICH_DATA CI_END="1.087800547380465" CI_START="0.5463141253662498" EFFECT_SIZE="0.7708961049422202" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="75" LOG_CI_END="0.036549273015882996" LOG_CI_START="-0.2625575703268792" LOG_EFFECT_SIZE="-0.1130041486554981" ORDER="2013" O_E="-8.429118773946357" SE="0.17569684038229194" STUDY_ID="STD-HDFP" TOTAL_1="1088" TOTAL_2="1000" VAR="32.394560858044194" WEIGHT="11.16081391799217"/>
<DICH_DATA CI_END="1.0429705475824245" CI_START="0.5358401827870445" EFFECT_SIZE="0.7475730926525314" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="80" LOG_CI_END="0.018272044569356626" LOG_CI_START="-0.2709647216566433" LOG_EFFECT_SIZE="-0.12634633854364336" ORDER="2014" O_E="-10.078505817513772" SE="0.16989910822623608" STUDY_ID="STD-MRC" TOTAL_1="4116" TOTAL_2="4049" VAR="34.6431840671355" WEIGHT="11.935526232146431"/>
<DICH_DATA CI_END="1.1928671420916643" CI_START="0.7031485003415021" EFFECT_SIZE="0.9158399107204311" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="127" LOG_CI_END="0.07659207596745592" LOG_CI_START="-0.152952945153491" LOG_EFFECT_SIZE="-0.038180434593017544" ORDER="2015" O_E="-4.835546875000006" SE="0.13483588167262422" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="55.00333736853471" WEIGHT="18.950156970142174"/>
<DICH_DATA CI_END="0.9192762108281454" CI_START="0.5208916845934854" EFFECT_SIZE="0.6919850678049265" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="123" LOG_CI_END="-0.036553978477597344" LOG_CI_START="-0.28325257549874683" LOG_EFFECT_SIZE="-0.15990327698817208" ORDER="2016" O_E="-17.53333333333333" SE="0.14491197706797337" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="47.62022429721851" WEIGHT="16.40647219893794"/>
<DICH_DATA CI_END="2.4509119019005303" CI_START="0.2808692289989559" EFFECT_SIZE="0.8296901447113655" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.3893277008048746" LOG_CI_START="-0.551495837900476" LOG_EFFECT_SIZE="-0.08108406854780068" ORDER="2017" O_E="-0.6113074204947004" SE="0.5526444037871491" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="3.274224446579775" WEIGHT="1.1280600448375404"/>
<DICH_DATA CI_END="0.7870423643666449" CI_START="0.31091055311839855" EFFECT_SIZE="0.4946713826701983" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="51" LOG_CI_END="-0.10400189011173527" LOG_CI_START="-0.5073645366145623" LOG_EFFECT_SIZE="-0.3056832133631488" ORDER="2018" O_E="-12.53778213935231" SE="0.2369372152330628" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="17.81285121455832" WEIGHT="6.137015365812527"/>
<DICH_DATA CI_END="0.9837622151314763" CI_START="0.5124943655438856" EFFECT_SIZE="0.7100511194905994" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="86" LOG_CI_END="-0.00710986207251253" LOG_CI_START="-0.2903109049583552" LOG_EFFECT_SIZE="-0.14871038351543386" ORDER="2019" O_E="-12.373486297004462" SE="0.16635369445891532" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="36.13558578535188" WEIGHT="12.449699520091116"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.724964372334085" CI_END="1.0682307393105004" CI_START="0.8467597563989353" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9510703447150551" ESTIMABLE="YES" EVENTS_1="653" EVENTS_2="657" I2="21.414318284918362" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.028665071031403498" LOG_CI_START="-0.07223979069654679" LOG_EFFECT_SIZE="-0.02178735983257166" METHOD="PETO" NO="7" P_CHI2="0.23945854542379785" P_Q="1.0" P_Z="0.3973351393272391" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11668" TOTAL_2="11295" WEIGHT="100.00000000000001" Z="0.8463901512532704">
<NAME>All Cause Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6571783811696175" CI_START="0.04945160585591492" EFFECT_SIZE="0.2862693349601788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2193692590457697" LOG_CI_START="-1.3058196008708707" LOG_EFFECT_SIZE="-0.5432251709125505" ORDER="2020" O_E="-1.558379120879121" SE="0.8959034861216529" STUDY_ID="STD-Australian" TOTAL_1="745" TOTAL_2="711" VAR="1.2458838234136147" WEIGHT="0.43770039066526256"/>
<DICH_DATA CI_END="0.9506441155355394" CI_START="0.40625810073544544" EFFECT_SIZE="0.6214554471985869" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="64" LOG_CI_END="-0.021982035729146605" LOG_CI_START="-0.39119796614937" LOG_EFFECT_SIZE="-0.20659000093925828" ORDER="2021" O_E="-10.113207547169807" SE="0.21687926517717074" STUDY_ID="STD-CASTEL" TOTAL_1="232" TOTAL_2="192" VAR="21.2600329740525" WEIGHT="7.469014817772338"/>
<DICH_DATA CI_END="2.100235198070248" CI_START="0.7237607765404842" EFFECT_SIZE="1.2329103202881304" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.32226793259315945" LOG_CI_START="-0.1404049567260301" LOG_EFFECT_SIZE="0.09093148793356469" ORDER="2022" O_E="2.8346972176759415" SE="0.27177634545383106" STUDY_ID="STD-Coope" TOTAL_1="297" TOTAL_2="314" VAR="13.538691464090082" WEIGHT="4.756374897534389"/>
<DICH_DATA CI_END="1.2469528831854277" CI_START="0.6279558045392946" EFFECT_SIZE="0.884890558760403" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="104" LOG_CI_END="0.09585004372780996" LOG_CI_START="-0.20207092078529437" LOG_EFFECT_SIZE="-0.05311043852874221" ORDER="2023" O_E="-3.99317406143345" SE="0.175000249287556" STUDY_ID="STD-EWPHE" TOTAL_1="287" TOTAL_2="299" VAR="32.652968196096246" WEIGHT="11.471548684733921"/>
<DICH_DATA CI_END="1.5266987964599896" CI_START="0.7191301682629149" EFFECT_SIZE="1.0478049257304825" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="55" LOG_CI_END="0.1837533632264206" LOG_CI_START="-0.14319249175664164" LOG_EFFECT_SIZE="0.020280435734889458" ORDER="2024" O_E="1.266094420600858" SE="0.19204961362513426" STUDY_ID="STD-HDFP" TOTAL_1="1180" TOTAL_2="1150" VAR="27.112722212841778" WEIGHT="9.525165092877074"/>
<DICH_DATA CI_END="1.7092645535639726" CI_START="0.9193483147151693" EFFECT_SIZE="1.2535587288681032" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="72" LOG_CI_END="0.23280928639604348" LOG_CI_START="-0.036519915709653926" LOG_EFFECT_SIZE="0.0981446853431948" ORDER="2025" O_E="9.029015169756804" SE="0.15820530651793868" STUDY_ID="STD-MRC" TOTAL_1="4177" TOTAL_2="4129" VAR="39.953783045247974" WEIGHT="14.036450364645678"/>
<DICH_DATA CI_END="1.1304547991020852" CI_START="0.6726719840782458" EFFECT_SIZE="0.872023665173586" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="135" LOG_CI_END="0.05325320189323516" LOG_CI_START="-0.1721966597463535" LOG_EFFECT_SIZE="-0.059471728926559185" ORDER="2026" O_E="-7.808203125000006" SE="0.132430364721908" STUDY_ID="STD-MRC-elderly" TOTAL_1="1273" TOTAL_2="1287" VAR="57.01968972442019" WEIGHT="20.03199656257616"/>
<DICH_DATA CI_END="1.2798845650249502" CI_START="0.6825737445138549" EFFECT_SIZE="0.9346740608867707" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="87" LOG_CI_END="0.10717080165302852" LOG_CI_START="-0.16585042105599238" LOG_EFFECT_SIZE="-0.02933980970148189" ORDER="2027" O_E="-2.626666666666665" SE="0.1603740176961276" STUDY_ID="STD-Shep" TOTAL_1="1120" TOTAL_2="1130" VAR="38.88051254384664" WEIGHT="13.659391999391577"/>
<DICH_DATA CI_END="4.421145663518203" CI_START="0.48463096859637966" EFFECT_SIZE="1.4637705097509344" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="0.645534823845035" LOG_CI_START="-0.3145888372872658" LOG_EFFECT_SIZE="0.16547299327888457" ORDER="2028" O_E="1.1978798586572452" SE="0.5639813912378865" STUDY_ID="STD-Shep-Pilot" TOTAL_1="229" TOTAL_2="54" VAR="3.143912503722587" WEIGHT="1.1045104729961153"/>
<DICH_DATA CI_END="1.208840421381183" CI_START="0.39214104937542293" EFFECT_SIZE="0.688502687988831" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.08236897357558817" LOG_CI_START="-0.40655769331798813" LOG_EFFECT_SIZE="-0.1620943598712" ORDER="2029" O_E="-4.5250245338567225" SE="0.2871979443593208" STUDY_ID="STD-STOP" TOTAL_1="510" TOTAL_2="509" VAR="12.123760426287193" WEIGHT="4.259285316329412"/>
<DICH_DATA CI_END="1.4515830776683027" CI_START="0.7666901301512484" EFFECT_SIZE="1.054947590519482" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="75" LOG_CI_END="0.16184189661992476" LOG_CI_START="-0.11538012752039283" LOG_EFFECT_SIZE="0.023230884549765962" ORDER="2030" O_E="2.01720841300191" SE="0.16284158925117379" STUDY_ID="STD-Syst_x002d_eur" TOTAL_1="1618" TOTAL_2="1520" VAR="37.71111172021089" WEIGHT="13.248561400478083"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>African American Women: Hypertension Treatment versus Placebo or Usual Care</NAME>
<DICH_OUTCOME CHI2="1.3191821482916155" CI_END="1.1093955103855886" CI_START="0.268016344833165" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5452853653527381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.045086403999360675" LOG_CI_START="-0.5718387199473358" LOG_EFFECT_SIZE="-0.26337615797398756" METHOD="PETO" NO="1" P_CHI2="0.5170627676176209" P_Q="1.0" P_Z="0.09423165712560551" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1605" TOTAL_2="1601" WEIGHT="99.99999999999999" Z="1.6734860163034917">
<NAME>Fatal Cerebrovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0049003472492326" CI_START="0.21441974225926838" EFFECT_SIZE="0.46418797211197715" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="0.002122996298203284" LOG_CI_START="-0.6687352303620391" LOG_EFFECT_SIZE="-0.333306117031918" ORDER="2031" O_E="-4.942222222222222" SE="0.39406544314200553" STUDY_ID="STD-HDFP" TOTAL_1="1344" TOTAL_2="1356" VAR="6.439665309968484" WEIGHT="84.56748485921494"/>
<DICH_DATA CI_END="7.774603232035604" CI_START="0.1517040155266897" EFFECT_SIZE="1.0860195805907833" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8906782345433271" LOG_CI_START="-0.8190029235112081" LOG_EFFECT_SIZE="0.035837655516059476" ORDER="2032" O_E="0.08181818181818179" SE="1.0042751752994568" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="0.9915041698827163" WEIGHT="13.020709903138652"/>
<DICH_DATA CI_END="362.6661159962522" CI_START="0.03863940685288182" EFFECT_SIZE="3.7434213772608627" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.559506981212433" LOG_CI_START="-1.4129695489878475" LOG_EFFECT_SIZE="0.5732687161122925" ORDER="2033" O_E="0.24242424242424243" SE="2.333452377915607" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="0.18365472910927455" WEIGHT="2.4118052376463965"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8985449379086075" CI_END="0.6989575393934027" CI_START="0.31286980211976645" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4676352286132138" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.1555492061817084" LOG_CI_START="-0.5046363524998362" LOG_EFFECT_SIZE="-0.33009277934077225" METHOD="PETO" NO="2" P_CHI2="0.638092242328965" P_Q="1.0" P_Z="2.100282535091163E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1492" TOTAL_2="1432" WEIGHT="100.0" Z="3.7066386768365778">
<NAME>Fatal and Non-Fatal Cerebrovascular Accidents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8517343035249855" CI_START="0.3247108762380796" EFFECT_SIZE="0.5258967503413845" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="44" LOG_CI_END="-0.06969586122976208" LOG_CI_START="-0.48850316437346275" LOG_EFFECT_SIZE="-0.2790995128016124" ORDER="2034" O_E="-10.618693134822166" SE="0.24600948299619538" STUDY_ID="STD-HDFP" TOTAL_1="1231" TOTAL_2="1187" VAR="16.52328156070707" WEIGHT="69.47670660813324"/>
<DICH_DATA CI_END="0.8068092099872952" CI_START="0.17458912147248778" EFFECT_SIZE="0.37531335063862803" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.09322915281942233" LOG_CI_START="-0.7579828203764767" LOG_EFFECT_SIZE="-0.42560598659794957" ORDER="2035" O_E="-6.427272727272728" SE="0.39047959490673795" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="6.558481710875581" WEIGHT="27.576950011242907"/>
<DICH_DATA CI_END="2.3894166691583596" CI_START="0.022108899236608765" EFFECT_SIZE="0.22984205962507276" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.37829188911261763" LOG_CI_START="-1.6554328796450433" LOG_EFFECT_SIZE="-0.6385704952662128" ORDER="2036" O_E="-1.0303030303030303" SE="1.1946199962682154" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="0.7007134279861552" WEIGHT="2.9463433806238513"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.338189256542609" CI_END="1.3284238220316085" CI_START="0.4643154737099404" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7853710818550527" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" I2="14.463724679099602" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.12333665500532358" LOG_CI_START="-0.33318684285792" LOG_EFFECT_SIZE="-0.10492509392629822" METHOD="PETO" NO="3" P_CHI2="0.31064811400112335" P_Q="1.0" P_Z="0.3676219440305062" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1605" TOTAL_2="1601" WEIGHT="100.0" Z="0.9009367803960504">
<NAME>Fatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7794262223593533" CI_START="0.5182611768256745" EFFECT_SIZE="0.9603163687423134" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.2502799862221633" LOG_CI_START="-0.2854513231340066" LOG_EFFECT_SIZE="-0.017585668455921674" ORDER="2037" O_E="-0.40888888888888886" SE="0.314691223028565" STUDY_ID="STD-HDFP" TOTAL_1="1344" TOTAL_2="1356" VAR="10.097892417401964" WEIGHT="72.61598216321345"/>
<DICH_DATA CI_END="1.1600678771680377" CI_START="0.14799784340004532" EFFECT_SIZE="0.4143519566968862" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.06448340113820307" LOG_CI_START="-0.8297446130258801" LOG_EFFECT_SIZE="-0.3826306059438385" ORDER="2038" O_E="-3.1931818181818183" SE="0.5252739620200423" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="3.6243343365838965" WEIGHT="26.063319617601127"/>
<DICH_DATA CI_END="362.6661159962522" CI_START="0.03863940685288182" EFFECT_SIZE="3.7434213772608627" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.559506981212433" LOG_CI_START="-1.4129695489878475" LOG_EFFECT_SIZE="0.5732687161122925" ORDER="2039" O_E="0.24242424242424243" SE="2.333452377915607" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="0.18365472910927455" WEIGHT="1.3206982191854346"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.369090296004809" CI_END="0.9337386670144264" CI_START="0.4662076858901453" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6597849219063321" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-0.02977465626941416" LOG_CI_START="-0.3314205709866908" LOG_EFFECT_SIZE="-0.18059761362805243" METHOD="PETO" NO="4" P_CHI2="0.5043196173972326" P_Q="1.0" P_Z="0.018930866988479605" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1507" TOTAL_2="1440" WEIGHT="100.0" Z="2.3468895226817392">
<NAME>Fatal and Nonfatal Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0553749827662677" CI_START="0.4927472251677299" EFFECT_SIZE="0.7211332014749559" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="63" LOG_CI_END="0.023406795189470662" LOG_CI_START="-0.30737581270602554" LOG_EFFECT_SIZE="-0.1419845087582774" ORDER="2040" O_E="-8.659565751741091" SE="0.19430334127813126" STUDY_ID="STD-HDFP" TOTAL_1="1246" TOTAL_2="1195" VAR="26.487408059861973" WEIGHT="83.15905818427017"/>
<DICH_DATA CI_END="1.0646163324980167" CI_START="0.1845187798251565" EFFECT_SIZE="0.4432174484995679" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.027193124488770253" LOG_CI_START="-0.7339594259310676" LOG_EFFECT_SIZE="-0.3533831507211487" ORDER="2041" O_E="-4.070454545454545" SE="0.4471047758825031" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="5.002434169035562" WEIGHT="15.705489687237343"/>
<DICH_DATA CI_END="6.263215706039109" CI_START="0.009246391892041392" EFFECT_SIZE="0.24064942743008205" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7967973691225603" LOG_CI_START="-2.034027703700848" LOG_EFFECT_SIZE="-0.6186151672891438" ORDER="2042" O_E="-0.5151515151515151" SE="1.662840660586576" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="0.36165854347672527" WEIGHT="1.1354521284924894"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.756234130999173" CI_END="0.9625251524072516" CI_START="0.45624766225170815" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6626838240399999" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.016587912823150783" LOG_CI_START="-0.34079934779307824" LOG_EFFECT_SIZE="-0.17869363030811455" METHOD="PETO" NO="5" P_CHI2="0.41556504590383947" P_Q="1.0" P_Z="0.030732229571174833" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1605" TOTAL_2="1601" WEIGHT="100.00000000000001" Z="2.1605226830022555">
<NAME>Fatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.063634438853566" CI_START="0.459010746428552" EFFECT_SIZE="0.6987271554085253" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="53" LOG_CI_END="0.026792390677137713" LOG_CI_START="-0.3381771465760584" LOG_EFFECT_SIZE="-0.1556923779494603" ORDER="2043" O_E="-7.799999999999997" SE="0.21438491281087374" STUDY_ID="STD-HDFP" TOTAL_1="1344" TOTAL_2="1356" VAR="21.7576287513894" WEIGHT="78.9120676636009"/>
<DICH_DATA CI_END="1.1055563281842868" CI_START="0.20631574649992734" EFFECT_SIZE="0.4775915400706547" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.04358087481740518" LOG_CI_START="-0.6854676243920863" LOG_EFFECT_SIZE="-0.3209433747873406" ORDER="2044" O_E="-4.029545454545454" SE="0.4282466972839291" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="5.45270441132175" WEIGHT="19.77624420254711"/>
<DICH_DATA CI_END="99.4577376580336" CI_START="0.14682956204035927" EFFECT_SIZE="3.8214311536195464" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9976385762132511" LOG_CI_START="-0.833186496610157" LOG_EFFECT_SIZE="0.5822260398015471" ORDER="2045" O_E="0.48484848484848486" SE="1.662840660586576" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="0.36165854347672527" WEIGHT="1.3116881338520048"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1728423085518105" CI_END="0.7558346447902979" CI_START="0.43774126909902367" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5752043259916556" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="139" I2="36.96503621975258" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-0.12157320543776703" LOG_CI_START="-0.35878250731174643" LOG_EFFECT_SIZE="-0.24017785637475672" METHOD="PETO" NO="6" P_CHI2="0.204656861047539" P_Q="1.0" P_Z="7.21797621425279E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1515" TOTAL_2="1458" WEIGHT="99.99999999999999" Z="3.9689838860420728">
<NAME>Fatal and Nonfatal Cardiovascular Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8917858670427249" CI_START="0.479053678632117" EFFECT_SIZE="0.6536155599119022" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="101" LOG_CI_END="-0.049739414599097705" LOG_CI_START="-0.3196158205570735" LOG_EFFECT_SIZE="-0.18467761757808554" ORDER="2046" O_E="-16.920956627482767" SE="0.1585267367694697" STUDY_ID="STD-HDFP" TOTAL_1="1254" TOTAL_2="1213" VAR="39.791925996299184" WEIGHT="77.25624487899097"/>
<DICH_DATA CI_END="0.7137238497810126" CI_START="0.2152907841903443" EFFECT_SIZE="0.3919925602797911" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="35" LOG_CI_END="-0.14646979062540572" LOG_CI_START="-0.6669745603341627" LOG_EFFECT_SIZE="-0.40672217547978423" ORDER="2047" O_E="-10.01818181818182" SE="0.30574707826708786" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="10.697329392496096" WEIGHT="20.76892430828224"/>
<DICH_DATA CI_END="1.5280332136476888" CI_START="0.031344031049113354" EFFECT_SIZE="0.21884862460762602" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.18413279425743748" LOG_CI_START="-1.5038451511409443" LOG_EFFECT_SIZE="-0.6598561784417534" ORDER="2048" O_E="-1.5454545454545459" SE="0.991526600752597" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="1.0171646535282899" WEIGHT="1.9748308127267842"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8766458517318865" CI_END="0.8499661091835241" CI_START="0.4918443616086862" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6465686648457295" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="134" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="-0.07059839062455085" LOG_CI_START="-0.30817230289906683" LOG_EFFECT_SIZE="-0.18938534676180885" METHOD="PETO" NO="7" P_CHI2="0.645117447025056" P_Q="1.0" P_Z="0.001779108237888355" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1605" TOTAL_2="1601" WEIGHT="100.0" Z="3.1248250727450873">
<NAME>All Cause Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9190959635281294" CI_START="0.49220628214806483" EFFECT_SIZE="0.6725955747293272" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="100" LOG_CI_END="-0.036639141220068845" LOG_CI_START="-0.30785284759211917" LOG_EFFECT_SIZE="-0.17224599440609403" ORDER="2049" O_E="-15.626666666666665" SE="0.15931227365244097" STUDY_ID="STD-HDFP" TOTAL_1="1344" TOTAL_2="1356" VAR="39.40048142933597" WEIGHT="76.73159600460481"/>
<DICH_DATA CI_END="0.9601015996005546" CI_START="0.29581675248535927" EFFECT_SIZE="0.5329297676522065" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="33" LOG_CI_END="-0.017682806740477796" LOG_CI_START="-0.5289772349843765" LOG_EFFECT_SIZE="-0.27333002086242725" ORDER="2050" O_E="-6.977272727272727" SE="0.3003368780987045" STUDY_ID="STD-Shep" TOTAL_1="211" TOTAL_2="229" VAR="11.086199147197801" WEIGHT="21.590136042246645"/>
<DICH_DATA CI_END="10.564150370030205" CI_START="0.15486970219971533" EFFECT_SIZE="1.2790882775631984" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.0238345743229955" LOG_CI_START="-0.8100335367565259" LOG_EFFECT_SIZE="0.10690051878323474" ORDER="2051" O_E="0.21212121212121193" SE="1.0772232062416656" STUDY_ID="STD-Shep-Pilot" TOTAL_1="50" TOTAL_2="16" VAR="0.8617644981281344" WEIGHT="1.6782679531485474"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>